SUBJECT INDEX: VOLUME 38(1998)

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parentheses following the page number indicates that the subject entry appeared in a letter to the editor; an "E" in parentheses indicates that the subject was discussed in an editorial; a "/" between numbers indicates on what page the correction for the subject entry appears.

In Volume 38 (1998), Number One (January) contains pages 1-117; Number Two (February), pages 118-220; Number Three (March), pages 221-322; Number Four (April), pages 323-418; Number Five (May), pages 419-516; Number Six (June), pages 517-618; Number Seven (July), pages 619-706; Number Eight (August), pages 707-802; Number Nine (September), pages 803-898; Number Ten (October), pages 899-996; Number Eleven/Twelve (November/December), pages 997-1152.

A
A antigen, 975
  in animals, 975
  antibodies, 975
  biochemical nature, 975
  bone, 975
  cardiovascular tissue, 975
  corneal tissue, 975
  genetic regulation, 975
  human cell and tissue distribution, 975
  in human fetal development, 975
  skin, 975
A transferase, *cis*AB blood type, 441
ABO incompatibility
  acute hemolysis, 51
  bedside test for, 997(E),1030
  bone transplantation, 975
  cornea transplantation, 975
  heart transplant, 975
  hemolytic transfusion reaction, 51, 999(E), 1030, 1071
  skin transplantation, 975
ABO testing
  errors, 999(E), 1030, 1071
  monoclonal reagent, 343
ABO-incompatible plasma
  apheresis platelet, 51
  hemoglobin, 51
  transfusion complication, 51
ACD-A solution, 318(L)
Activated partial thromboplastin time, effect of red cell transfusion on, 1011
Active errors, 999(E), 1071
Acute anemia, red cell, 517(E)
Acute normovolemic hemodilution, 400
  advantages, 473
  as alternative to allogeneic blood transfusion, 477
  clinical studies, 473
  hemorrhage
    hyperoxic ventilation, 135
    management, 135
  preoperative autologous blood donation, compared, 473
  prostatectomy, 924
  reasons for underuse, 473
Acute thrombosis, antithrombin III, 481
Administration
  blood component preparation system, 860
  Food and Drug Administration
    error reporting system, 999(E), 1030,1071
    regulation of blood bank software, 86
  home transfusion, nationwide survey, 90
  ISO 9000 registration, 75, 79
  no-fault compensation in Italy, 596
Adsol red cell unit, 429
Adult T-cell leukemia, 1056, 1118(L)
Africa
  human T-lymphotropic virus type I, in 1969, 612(L)
  human T-lymphotropic virus type II, in 1969, 612(L)
Alanine aminotransferase
  blood donor, Brazil, 410(L)
  GB virus C, 378
  hepatitis C virus, 378, 1097
  hepatitis G virus, 378, 1097
Albumin. *See also* Human albumin
  as predictor of CD34+ cell collection efficiency, 1046
  plasma exchange, 834
  transmissible spongiform encephalopathy, 810
Allele-specific polymerase chain reaction, 118(E)
  C733G (Leu245Val) polymorphism, 951
  D-CE hybrid exon 3, 951
  DVII, T329C mutation in exon 2, 1015
  G1006T (Gly336Cys) polymorphism, 951
  HLA typing, 118(E)
Allele-specific primer polymerase chain reaction
  Duffy blood group locus, 118(E)
  Duffy (Fy) blood group system, 168
  ethnic population, 168
  Fc γ receptor IIA polymorphism, 174
  FcγRIIa receptor, 118(E)
  FY glycoprotein, 168
  immunohematology, 168
  Y chromosome in sample of female blood, 1041
Allergic reaction
  duration of platelet storage, 229
  lymphocytotoxic antibody, 229
Allogeneic blood transfusion
  objections to, 757
  perceptions of, 757
  physician recommendations, 757
  prevention of graft-versus-host disease, 1117(L)
Allogeneic cell contamination of sample for polymerase chain reaction, 1041
Alloimmunization to multiple red cell antigens, 1022,1026
American Association of Blood Banks
  evaluation, 899(E)
  functions, 899(E)
  future directions, 899(E)
  history, 899(E)
  major activities, 899(E)
  role, 899(E)
  standards for prevention of graft-versus-host disease, 1117(L)
American Association of Blood Banks institutional member, home transfusion
  component issued, 90
  error reporting system, 999(E), 1030, 1071
  informed consent, 90
  patient diagnosis, 90
  posttransfusion visit, 90
  transfusionists, 90
  written policies, 90
American Medical Association, Council on Scientific Affairs, report on crossover use of donated blood for autologous transfusion, 891
American National Standards Institute, 5
Amicus blood cell separator
  AS.TEC 204 blood cell separator, compared, 285
  blood collection, 285
  evaluation, 848
  platelet collection, 285

collection efficiency, ... 848
collection times, ... 848
component quality, ... 285
component yields, ... 848
double apheresis platelet, ... 848
incidence of donor reactions, ... 848
incidence of transfusion recipient reactions, ... 848
platelet yield, ... 285
residual white cells, ... 848
separation efficiency, ... 285
single apheresis platelet, ... 848
white cell contamination, ... 285
Spectra Leukocyte Reduction System, compared, ... 848
Amyloidosis, ... 60
Analysis of errors in transfusion, ... 999(E),1030,1071
Anemia
measures, ... 602
nitric oxide, ... 602
perioperative blood conservation, ... 924
red cell transfusion, ... 522
Angioedema, hepatitis G virus, ... 307
Angiotensin-converting enzyme inhibitor,
hypotensive reaction, ... 410(L)
red cells filtered at the bedside, ... 410(L)
red cells filtered before storage, ... 410(L)
Anti-A, ... 51, 975
Anti-B, ... 975
Antibody identification, p values, ... 1221(1997)/321
Antibody screening, ... 343
AutoVue System, ... 959
column agglutination technology, ... 959
pretransfusion testing instrument, ... 959
Yersinia enterocolitica, ... 511(L)
Antibody to hepatitis B core antigen
hepatitis B surface antigen mutant form, ... 56
screening, ... 56
Antibody to hepatitis *B e* antigen, hepatitis B surface
antigen mutant form, ... 56
Anticoagulant, apheresis, ... 318(L)
Anti-D, ... 318(L)
delayed hemolytic transfusion reaction, ... 459
dose, ... 749
red cell acid-elution kit, ... 565
systemic inflammatory response syndrome mediator, ... 459
Anti-D preparation ... 68/419, 252
Anti-D prophylaxis, consensus conference, ... 97
antenatal anti-D prophylaxis, ... 97
ethical considerations of anti-D provision
by immunized volunteers, ... 97
guidelines, ... 97
immune-mediated thrombocytopenia, ... 97
monoclonal anti-D, ... 97
polyclonal anti-D, ... 97
Anti-Doa, ... 1022, 1026
Anti-Dob, ... 1022, 1026
Anti-E2 enzyme-linked immunosorbent assay
GB virus type C, ... 821
hepatitis G virus, ... 821
Anti-human immunodeficiency virus immunoblot, ... 776
Anti-human immunodeficiency virus-1/2 enzyme immunoassay, ... 469
Anti-IgG globulin reagent, ... 343
Anti-Jkb red cell alloantibody, ... 247
Anti-K red cell alloantibody, ... 247
Anti-M red cell alloantibody, ... 247
Antimicrobial therapy, thrombotic thrombocytopenia, ... 419
Anti-P1
anti-P1 agglutinin, ... 373
hemolytic transfusion reaction, ... 373
IgM, ... 373
indirect antiglobulin test, ... 373
indirect monocyte monolayer assay, ... 373
polyspecific anti-human globulin, ... 373
reacting at 37°C, ... 373
transfusion complications, ... 373
Anti-P1 agglutinin, anti-P1, ... 373
Antithrombin III
acute thrombosis, ... 481
bone marrow transplant-related venooclusive disease, ... 481
delivery, ... 481
disseminated intravascular coagulation, ... 481
drug-induced deficiency, ... 481
extracorporeal circuit, ... 481
function, ... 481
heparin resistance, ... 481
L-Ase therapy, ... 481
LeVeen peritoneovenous shunt, ... 481
liver dysfunction, ... 481
liver transplantation, ... 481
neonatal, ... 481
oral contraceptive, ... 481
perioperative period, ... 481
pregnancy, ... 481
renal dysfunction, ... 481
structure, ... 481
Antithrombin III concentrate, ... 481
acquired deficiency states, ... 481
congenital deficiency, ... 481
Anti-V, ... 951
Anti-VS, ... 951
Anxiety, in donors positive for human T-lymphotropic virus, ... 1056
Apheresis, ... 1
adverse effects
center-specific rates, ... 938
frequency, ... 938
nonvenipuncture symptoms, ... 938
pain or hematoma at venipuncture site, ... 938
platelet loss, ... 1051
procedure-specific rates, ... 938
unconsciousness, ... 938
anticoagulant, ... 318(L)
C3 activation product, ... 16
chemotaxin, ... 16
child, ... 944
granulocyte—colony-stimulating factor
granulocyte collection efficiency, ... 557, 1046
granulocyte collection yield, ... 557
hematocrit, ... 557
higher interface offset, ... 557
platelet count, ... 557
red cell volume, ... 557
improved blood flow during, ... 703(L)
peripheral blood stem cell
age-specific intra-apheresis recruitment, ... 944
CD34+ cell, ... 944, 1046, 1063
chemotherapy, ... 944
collection efficiency, ... 944, 1046, 1051, 1063
colony-forming units—granulocyte-macrophage, .. 944, 1063
comparison of systems, ... 1051
granulocyte—colony-stimulating
factor, ... 944, 1046, 1051, 1063
optimal duration, ... 944
selective enrichment of more immature progenitors, ... 1063
platelet, p-selectin, ... 24
platelet concentrate, transforming growth factor beta1, ... 156
terminal complement complex, ... 16
thrombopoietin, ... 449
white cell subset, ... 650
Apheresis platelet
ABO-incompatible plasma, ... 51
hemoglobin, ... 51
non-group O autologous bone marrow transplant, ... 51
Apheresis system, selective enrichment of more immature
progenitors, ... 1063
Apheresis system, white cell-reduced platelet component
clinical trial, ... 966
collection efficiency, ... 966
component quality, ... 966
determination of degree of conformance with standards, ... 966
ongoing quality control, ... 966

validation, ... 966
Apoptosis of white cells in stored red cells, ... 1082
Aprotinin, ... 9
Artificial organ transplant, ... 9
AS104 apheresis machine, pediatric leukapheresis, ... 71
AS.TEC 204 blood cell separator
Amicus blood cell separator, compared, ... 285
blood collection, ... 285
platelet collection, ... 285
component quality, ... 285
platelet yield, ... 285
separation efficiency, ... 285
white cell contamination, ... 285
ATP, red cell, 24-hour storage at 25°C, ... 424
Australia
GB virus type C, ... 821
hepatitis G virus, ... 821
Autoimmune hemolytic anemia, ... 225(E)
red cell-bound immunoprotein, ... 782
Autologous blood donation
adverse events in donors with cardiac disease, ... 669
cardiac disease, safety, ... 669
cardiac surgery, ... 669
crossover use, ... 891
costs, ... 891
potential benefits, ... 891
potential risks, ... 891
donor perceptions, ... 757
donor preferences, ... 757
erythropoiesis, compensatory, ... 613(L)
hip surgery, interhospital variations, ... 530
hospital-specific differences, ... 530
iron supplementation, ... 764
intravenous iron, ... 764
oral iron supplementation, ... 764
knee surgery, interhospital variations, ... 530
motivations, ... 757
physician recommendations, ... 757
prostatectomy, ... 924
requirements, ... 891
standards, ... 891
Autologous blood transfusion
adverse reaction, ... 296
allergic reaction, ... 296
evaluation at large academic hospital, ... 296
febrile nonhemolytic reaction, ... 296
incidence, ... 296
incidence at large academic hospital, ... 296
annotated bibliography, ... 400
reviews, ... 400
transfusion complication, ... 296
Automated microbiologic blood culture device, ... 674, 1090
Enterococcus faecalis, ... 1090
Escherichia coli, ... 674, 1090
Pseudomonas putida, ... 1090
Staphylococcus aureus, ... 1090
Staphylococcus epidermidis, ... 674
AutoPBSC system, collection of CD34+ cells, ... 1051
AutoVue System
antibody screen, ... 959
crossmatch, ... 959
evaluation, ... 959
forward ABO group, ... 959
phenotype, ... 959
reverse ABO group, ... 959
Rh type, ... 959
variant A antigen, ... 959
variant D antigen, ... 959
weak A antigen, ... 959
weak D antigen, ... 959

B

B antigen, ... 975
in animals, ... 975
antibodies, ... 975
biochemical nature, ... 975
bone, ... 975
cardiovascular tissue, ... 975
corneal tissue, ... 975
genetic regulation, ... 975
human cell and tissue distribution, ... 975
in human fetal development, ... 975
skin, ... 975
B transferase, *cis*AB blood type, ... 441
BacT/Alert system, ... 1090
Bacteria
automated microbiologic blood culture device
evaluation, ... 674, 1090
platelet component, ... 674/898
sampling times, ... 674
human albumin, ... 690
reporting of, ... 999(E)), 1030, 1071
Bacteriophage inactivation, dimethylmethylene blue, ... 729
Bacteriophage R17, dimethylmethylene blue, ... 729
Baumgartner perfusion chamber, ... 997(E), 1004
Bedside pretransfusion check, ... 999(E), 1030, 1071
Behavior, human, classification of for error reporting, ... 999(E),1071
Biological response modifiers and white cell apoptosis in stored red cells, ... 1082
Bleeding time, effect of red cell transfusion on, ... 1011
Bleomycin, ... 225(E)
Blood bank software, Food and Drug Administration
current regulation status, ... 86
internationally developed software, ... 86
regulation, ... 86
regulation future, ... 86
regulation history, ... 86
Blood cell analyzer and contamination of sample for polymerase chain reaction, ... 1041
Blood cell separator, ... 24, 285, 848, 944, 1046, 1051, 1063
See also Specific type
Blood collection, ... 45
United States, 1994, ... 625
Blood component
C1 inhibitor concentrate, ... 540
cellular, irradiation for prevention of graft-versus-host disease, ... 1117(L)
CP2D, ... 242
CPDA-1 packed red cell, ... 424
cryopreservation
dimethyl sulfoxide concentration, ... 160
second-messenger effectors, ... 160
single-donor platelet, ... 160
cytokine mRNA, ... 236
detection of bacteria in, ... 1090
filtration, ... 16
granulocytes, ... 557, 722
neutrophil, ... 713
nucleic acid testing, committee report, ... 989
platelet, ... 550
platelet concentrate, ... 16
platelet storage, ... 229
red cell, ... 729
storage, ... 16,1082
transmissible spongiform encephalopathy
Cohn plasma fraction, ... 810
distribution of infectivity, ... 810
experimental models, ... 810
scrapie, ... 810
United States, 1994, ... 625
in vitro platelet assay, ... 31
white cell reduction in platelet components, ... 966
white cell subsets, ... 650
white cell-reduced red cell, ... 429
white cells and false-positive result in BacT/Alert system, ... 1090
white cells in fresh-frozen plasma, ... 645
Blood component preparation system

administration, 860
buffy coat method, 860
component specifications, 860
efficiency, 860
process costs, 860
Blood donor. *See also* Autologous blood donation
adverse events in donors with cardiac disease, 669
alanine aminotransferase, Brazil, 410(L)
all-volunteer blood supply, 874
apheresis donors
adverse effects, 938
hepatitis B surface antigen, 350
incidence of human immunodeficiency virus, 350
incidence of human T-lymphotropic virus, 350
incidence of viral infections, 350
prevalence of viral infections, 350
unreported risk behaviors, 350
whole-blood donors compared, 350
attitudes about exporting and importing blood, 210(L)
cocaine, 512(L)
communication, 45
community service credit, 45
cytomegalovirus DNA, 271
deferral
deferral status understanding, 45
negative effects, 181
permanently deferred donors, 45
reasons for, 181
reasons for deferral, 45
recruitment of deferred donor, 45
return donation motivation of deferred donors, 45
short-term temporary deferral effect on future donation, 181
deferral registry, 45
mail survey, 45
Precheck system, 45
donation experience, 323(E)
donor platelet count effects on platelet yields, 619(E)
donor return rates, 181
GB agent
infectivity, 290
prevalence, 290
volunteer blood donors in Taiwan, 290
hemoglobin
additional donations, 855
female plateletpheresis donors, 855
frequency of donor reactions, 855
hemoglobin cutoff of 12.5 g per dL, 855
standards of the American Association of Blood Banks, 855
hepatitis C virus, 512(L), 1097
hepatitis G virus
infectivity, 290, 1097
prevalence, 290, 1097
volunteer blood donors in Taiwan, 290
human immunodeficiency virus
donor selection criteria identification, 279
exclusion strategy, 279
risk factors in first-time blood donors in Zimbabwe, 279
self-administered survey, 279
human T-lymphotropic virus, 1056, 1118(L)
incentives. *See also* Specific type 45, 323(E).
intranasal drug use, 512(L)
iron supplementation, 764
monetary incentives, 874
safety record, 883
transfusion risk, 874
new recruitment strategies, 323(E)
nonmonetary incentives, 874
notification, 1056
paid "pedigree" donors, 323(E)
perceptions about resource sharing, 210(L)
peripheral blood stem cell, 944, 1046, 1051
replacement donor, 368
drawbacks, 368
repeat replacement donors, 368
replacement-donor effect *vs.* new-donor effect, 368
retention rate, 368
safer replacement-donor subgroup, 368
retention, 359
reticulated platelet, 454
safe donors
defined, 359
donation experience, 359
intention to donate again, 359
physical effects of blood donation, 359
projected loss among, 359
survey, 359
test results as motivation, 45
thrombopoietin, 449
transfusion safety, 323(E)
blood donor characteristics, 323(E)
Trypanosoma cruzi, screening in nonendemic area of Brazil, 611(L)
voluntary nonremunerated, 803(E)
benefits, 803(E)
ethical aspects, 803(E)
lower risk, 803(E)
volunteer donors, 874
whole-blood donors
apheresis donors compared, 350
deferrable risk behaviors, 350
demographics, 350
hepatitis B surface antigen, 350
incidence of human immunodeficiency virus, 350
incidence of human T-lymphotropic virus, 350, 1118(L)
incidence of viral infections, 350
prevalence of viral infections, 350
unreported risk behaviors, 350
Yersinia enterocolitica, 511(L)
Blood grouping, bedside as ABO check, 999(E), 1030, 1071
Blood oxygen, 135
Blood transfusion. *See also* Specific type
hip replacement, prospective validation of point score system for predicting, 932
knee replacement, prospective validation of point score system for predicting, 932
Bone
A antigen, 975
B antigen, 975
immunogenic properties of red cell antigens, 975
Bone marrow transplantation. *See also* Unrelated-donor bone marrow transplantation
conditioning regimen, 247
immune hemolytic anemia
ABO-incompatible allogeneic, 247
multiple red cell alloantibodies, 247
platelet survival, 637
platelet transfusion, 839
venoocclusive disease, antithrombin III, 481
Bone transplantation, ABO incompatibility, 975
Bovine spongiform encephalopathy, 221(E)
Bovine virus diarrhea, dimethylmethylene blue, 729
Brazil
alanine aminotransferase, 410(L)
Trypanosoma cruzi, 611(L)
Breast cancer patients, immunomagnetic selection of CD34+ cells, 1063
Bristol card ABO compatibility test card, 1030
Buffy coat method, blood component preparation system, 860
component specifications, 860
efficiency, 860
process costs, 860
Buffy coat method platelet concentrate
C3 activation product, 16
chemotaxin, 16
complement activation, 16
cytokine mRNA, 236
filtration, 16
interferon γ, 236

interleukin-1β, 236
interleukin-2, 236
interleukin-6, 236
interleukin-8, 236
quality, 799(L)
storage, 16
terminal complement complex, 16
transforming growth factor β_1, 156
tumor necrosis factor α, 236
white cell reduction, 236
hypotensive reactions, 410(L)
white cell subset, 650
white cell-reduction filter, 650
granulocyte, 650
monocyte, 650
Burst-forming units—erythroid, CD34+ cell selection, 199, 1063
hematopoietic recovery, 199
neutrophils, 199
reticulocytes, 199
Bystander immune hemolysis, 225(E)

C

C1 inhibitor concentrate, hereditary angioedema
efficacy, 540
randomized controlled trial, 540
recovery of antigenic C1 inhibitor, 540
recovery of functional C1 inhibitor, 540
resolution of symptoms, 540
safety, 540
time-to-relief, 540
C3 activation product
apheresis, 16
platelet concentrate, 16
white cell reduction, 16
C3a-desArg
delayed hemolytic transfusion reaction, 459
systemic inflammatory response syndrome mediator, 459
C5a
filtration, 16
storage, 16
C733G (Leu245Val) polymorphism
allele-specific polymerase chain reaction, 951
polymerase chain reaction, 951
Calibration beads, 262
Canada, hepatitis C virus, 316(L)
Canadian Apheresis Group, national registry of apheresis, 834
Cancer
immunomagnetic selection of CD34+ cells, 1063
prediction of CD34+ cell collection efficiency after, 1046
transplantation, hematopoietic recovery, 199
Carbon dioxide
production by white cells and false-positive result in BacT/Alert system, 1090
red cell transfusion, 602
Cardiac disease, autologous blood donation, safety, 669
Cardiac surgery
autologous blood donation, 669
prevention of graft-versus-host disease in Japan, 1118(L)
Cardiopulmonary bypass, lung transplantation, 12, 1119(L)
Cardiovascular tissue
A antigen, 975
B antigen, 975
Causal Investigation Report, 999(E), 1071
CD11a, granulocyte—colony-stimulating factor, 663
CD11b, granulocyte—colony-stimulating factor, 663
CD13, granulocyte—colony-stimulating factor, 663
CD14, granulocyte—colony-stimulating factor, 663
CD16, granulocyte—colony-stimulating factor, 663
CD18, granulocyte—colony-stimulating factor, 663
CD32, granulocyte—colony-stimulating factor, 663
CD34+ cell, 1
collection efficiency, 1046, 1051, 1063
granulocyte, time to engraftment, 385, 0163
peripheral blood progenitor cell transplantation
autologous, 385
colony-forming units—granulocyte macrophage, 385, 1063
comparison of apheresis systems, 1051
cutoff value, 385
engraftment, 385, 1063
leukapheresis, 385
mononuclear cell, 385, 1046
threshold, 385
white cell count, 385, 1046
platelet, time to engraftment, 385, 1063
CD34+ cell enrichment, 1, 1063
CD34+ cell selection, 1063
burst-forming units—erythroid, 199, 1063
hematopoietic recovery, 199, 1063
neutrophils, 199
reticulocytes, 199
colony-forming units of multiple lineages, 199
colony-forming units—granulocyte-macrophage, 199, 1063
hematopoietic recovery, 199
neutrophils, 199
reticulocytes, 199
effectiveness in purging
clonotypic cells, 60
tumor cells, 1063
granulocyte—colony-stimulating factor, 60, 1046, 1051, 1063
immunoglobulin light-chain variable region genes, 60
large-volume leukapheresis, 60
lymphocyte, 60
mephalan, 60
neutrophil, 60
peripheral blood stem and progenitor cell, 199, 1046, 1051, 1063
platelet, 60
platelet recovery, 199
predictors of efficiency, 1046
purity, 60
reverse transcriptase polymerase chain reaction, 60
transplantation, 60
viability, 60
yield, 60
CD34+ Thy-1+ cell, 1
CD42a, 550
CD45 fluorescence, 262
CD45RC, 499
CD55, 337
CD58, 337
CD59, 337
CD62L, granulocyte—colony-stimulating factor, 663
CD64, granulocyte—colony-stimulating factor, 663
CD65, 499
CD65s, 499
CD66f, 499
CD95, 1082
CD114, 499
CD132, 499
CD134, 499
CD135, 499
CD138, 499
CD139, 499
CD140a, 499
CD140b, 499
CD141, 499
CD142, 499
CD143, 499
CD144, 499
CD146, 499
CD147, 499
CD148, 499
CD151, 499
CD152, 499
CD153, 499
CD154, 499
CD155, 499
CD156, 499
CD157, 499

CD158a, ... 499
CD158b, ... 499
CD161, ... 499
CD162, ... 499
CD163, ... 499
CD164, ... 499
CD165, ... 499
CD166, ... 499
CDw123, ... 499
CDw125, ... 499
CDw131, ... 499
CDw136, ... 499
CDw137, ... 499
CDw145, ... 499
CDw149, ... 499
CDw150, ... 499
Cell number
  dimethyl sulfoxide, ... 160
  second messenger effector mixture, ... 160
Cell separator. *See also* Specific type ... 29, 94, 848
  p-selectin, ... 24
  types compared, ... 285, 1051
Cell-free plasma, human immunodeficiency virus-1
  after storage, ... 580
  compartmentalization of human immunodeficiency virus-1, ... 580
  immediately after component preparation, ... 580
Central Africa, human herpesvirus 8, prevalence, ... 771
Central blood volume, red cell transfusion, ... 602
Chemotaxin
  apheresis, ... 16
  platelet concentrate, ... 16
  white cell reduction, ... 16
Chemotherapy
  granulocyte, ... 722
  peripheral blood stem and progenitor cells, ... 209, 1046
Child
  apheresis, ... 944
  GB virus type C, ... 821
  hepatitis G virus, ... 821
Chromium-51 red cell survival studies, ... 1026
Chronic myeloid leukemia, ... 247
Chronic viral hepatitis, hepatitis E virus antibody, ... 589
Circulating p-selectin, ... 24
*cis*AB blood type
  A transferase, ... 441
  B transferase, ... 441
  enzymatic studies, ... 441
  immunohematology, ... 441
  Israel, ... 441
  serologic studies, ... 441
Cisplatin, ... 225(E)
Citrate, ... 318(L)
Classification of causes of errors in transfusion, ... 999(E), 1030, 1071
Clinical Transfusion Process Improvement Project, ... 999(E)
Clostridium perfringens, ... 225(E)
Clotting factor concentrate, hepatitis A virus, ... 573
  United States, ... 573
Coagulation, platelet, ... 550, 997(E), 1004
Cobblestone area-forming cells, ... 1063
COBE Spectra apheresis machine, peripheral blood progenitor cell collection
  CD34+ cell enrichment, ... 70
  CD34+ cell extraction, ... 70
  CD34 cytofluorimetry, ... 70
  comparison of AutoPBSC and Version 4.7 systems, ... 1051
  extraction efficiency, ... 70
  mononuclear cell purity, ... 70
  platelet count decreases, ... 70, 1051
  red cell contamination, ... 70
Cocaine, blood donor, ... 512(L)
Cold shock and white cell apoptosis, ... 1082
Collaborative Hospital Transfusion Study, ... 530
Colony-forming units—granulocyte-macrophage, CD34+ cell selection, ... 199
  hematopoietic recovery, ... 199, 1063
  neutrophils, ... 199
  reticulocytes, ... 199
Column agglutination technology
  antibody screen, ... 959, 1037
  crossmatch, ... 959
  evaluation, ... 959, 1037
  forward ABO group, ... 959
  phenotype, ... 959, 1037
  reverse ABO group, ... 959
  variant A antigen, ... 959
  variant D antigen, ... 959
  weak A antigen, ... 959
  weak D antigen, ... 959
Commercial acid-elution kit, low-ionic wash solution
  acid elution, ... 565
  antigen-negative red cell, ... 565
  D+ red cell, ... 565
  D- red cell, ... 565
  false-positive eluate reactivity, ... 565
  IgG, ... 565
  phosphate-buffered saline, ... 565
Commercial polyclonal anti-D, ... 565
Committee report, solvent/detergent-treated plasma, ... 102
  development, ... 102
  efficacy, ... 102
  impact on blood banking and transfusion practice, ... 102
  logistics, ... 102
  production, ... 102
  safety, ... 102
  supply, ... 102
Common source-plasma pool, hepatitis A virus, ... 573
Communication, blood donor, ... 45
Community service credit, blood donor, ... 45
Compatibility misinterpretation errors, ... 1030
Competence of nurses in bedside blood grouping, ... 999(E), 1030
Competitive reverse transcription-polymerase chain reaction, cytokine mRNA, ... 236
Complement activation, buffy coat platelet concentration, ... 16
Complement component 1 inhibitor deficiency, hepatitis G virus
  enzyme-linked immunosorbent assay, ... 307
  nested polymerase chain reaction, ... 307
  steam-heated plasma concentrates of C1 inhibitor, ... 307
Confidential no-fault reporting of errors, ... 999(E), 1071
Consensus conference
  anti-D prophylaxis, ... 97
    antenatal anti-D prophylaxis, ... 97
    ethical considerations of anti-D provision by immunized volunteers, ... 97
    guidelines, ... 97
    immune-mediated thrombocytopenia, ... 97
    monoclonal anti-D, ... 97
    polyclonal anti-D, ... 97
  unrelated-donor bone marrow transplantation, ... 100
    decision-making, ... 100
    donor, ... 100
    efficacy, ... 100
    indications, ... 100
    toxicity, ... 100
Consultant, ISO 9000 registration, ... 75
Contamination of sample for polymerase chain reaction, ... 1041
Continuous-flow blood cell separator, granulocyte, ... 557
Copper
  fulminant Wilson's disease, ... 327
  plasma exchange, ... 327
  red cell, ... 327
  transfusion practice, ... 327
Cord blood banking
  accountability, ... 867
  allocating cord blood, ... 867
  coordination, ... 867
  current situation, ... 867

ethical issues
conference report, ... 867
workshop summary, ... 867
factors influencing availability, ... 508(L)
financial realities, ... 867
harvesting, ... 867
linkage, ... 867
oversight, ... 867
recruitment, ... 867
scientific overview, ... 867
societal issues, ... 867
unrelated donor blood, National Heart, Lung, and Blood Institute-sponsored trial, ... 807(E)
Cord blood progenitor cell, storage
temperature, ... 615(L)
time, ... 615(L)
Cornea transplantation, ABO incompatibility, ... 975
Corneal tissue
A antigen, ... 975
B antigen, ... 975
Coronary artery bypass graft surgery, transfusion practice
all blood components, ... 122
interhospital differences, ... 122
red cell, ... 122
variation by surgeon, ... 122
Corticosteroid, ... 710(E)
Cost-effectiveness, preoperative autologous blood donation, ... 400
CP2D
blood component, ... 242
plasma volume
aggregation, ... 242
glucose, ... 242
hypotonic shock response, ... 242
lactate, ... 242
morphology, ... 242
pCO_2, ... 242
pH, ... 242
pO_2, ... 242
CPD and saline-adenine-glucose-mannitol solution, ... 1082
CPDA-1, ... 242, 1082
CPDA-1 packed red cell
blood component, ... 424
storage, 24-hour storage at 25°C, ... 424
C-reactive protein
delayed hemolytic transfusion reaction, ... 459
systemic inflammatory response syndrome mediator, ... 459
Creutzfeldt-Jakob disease, ... 810
hemophilia
formalin-fixed paraffin block brain samples, ... 817
prion, ... 817
surveillance, ... 817
human albumin, ... 690
new variant, ... 221(E)
transfusion safety, ... 221(E)
donor pool size and risk, ... 312
white cell reduction, ... 221(E)
Creutzfeldt-Jakob Disease investigational Lookback Study, ... 622(E)
Cromer blood group antibody, hemagglutination inhibition, soluble recombinant decay-accelerating factor, ... 332
Crossmatch
AutoVue System, ... 959
column agglutination technology, ... 959
pretransfusion testing instrument, ... 959
Cryoprecipitate, transmissible spongiform encephalopathy, ... 810
Cryopreservation, blood component
dimethyl sulfoxide concentration, ... 160
second-messenger effectors, ... 160
single-donor platelet, ... 160
Cryoprotectant, ... 160
CS 3000 Plus cell separator
peripheral blood stem and progenitor cell collection, .. 1046, 1063
platelet, ... 24
gender, ... 24
p-selectin, ... 24
Cumulative frequency distributions and percentiles, in reporting blood usage, ... 12, 1119(L)
Cyclophosphamide, peripheral blood progenitor cell
CD34+ cell collection, ... 209
costs of mobilization, ... 209
engraftment, ... 209
Cyclosporine, ... 225(E)
Cys336, ... 951
Cytokine
febrile nonhemolytic reaction, ... 236
role in white cell apoptosis, ... 1082
transfusion-associated sepsis, ... 703(L)
white cell, ... 236
Cytokine mRNA
blood component, ... 236
competitive reverse transcription-polymerase chain reaction, ... 236
Cytomegalovirus DNA, peripheral blood mononuclear cell, ... 271
polymerase chain reaction, ... 271
seronegative carriers, ... 271
seronegative donors, ... 271
seropositive donors, ... 271
Cytotoxic white cell antibody, enzyme-linked immunosorbent assay, ... 41

D

D-CE hybrid exon 3
allele-specific polymerase chain reaction, ... 951
polymerase chain reaction, ... 951
D variants, genotyping by multiplex PCR, ... 1015
Decay-accelerating factor, ... 332
Delayed hemolytic transfusion reaction
anti-D, ... 459
anti-Do^a, ... 1022, 1026
anti-Do^b, ... 1022, 1026
C3a-desArg, ... 459
C-reactive protein, ... 459
direct antiglobulin test, ... 459
elastase, ... 459
exchange transfusion, ... 459
fibrinogen, ... 459
hemolysis, ... 459
interleukin-1, ... 459
interleukin-6, ... 459
interleukin-8, ... 459
interleukin-10, ... 459
neopterin, ... 459
septic-toxic syndrome, ... 459
tumor necrosis factor, ... 459
Depression, in donors positive for human T-lymphotropic virus, ... 1056
Detection sensitivity level, ... 999(E), 1071
Dexamethasone, neutrophil
adverse effects, ... 713
bactericidal activity, ... 713
CD11b, ... 713
CD14, ... 713
CD18, ... 713
CD32, ... 713
CD64, ... 713
chemiluminescence, ... 713
functions, ... 713
immunophenotype analysis, ... 713
kinetics, ... 713
morphology, ... 713
Dimethyl sulfoxide
cell number, ... 160
extent of shape change, ... 160
hypotonic shock response, ... 160
percent of discoid cells, ... 160
p-selectin, ... 160
Dimethylmethylene blue
bacteriophage inactivation, ... 729
bacteriophage R17, ... 729
bovine virus diarrhea, ... 729

encephalo-myocarditis virus, ... 729
phenothiazine derivative, ... 729
pseudorabies virus, ... 729
red cell, ... 729
red cell potassium efflux, ... 729
vesicular stomatitis virus, ... 729
Direct antiglobulin test, ... 247
delayed hemolytic transfusion reaction, ... 459, 1022, 1026
red cell-bound immunoprotein, ... 782
systemic inflammatory response syndrome mediator, ... 459
Discovery Report, ... 999(E), 1071
Disseminated intravascular coagulation, antithrombin III, ... 481
DNA electrophoresis evaluation of white cell apoptosis in stored red cells, ... 1082
DNA polymorphism, ... 118(E)
DNA typing
Fcγ receptor IIA polymorphism, ... 174
peripheral blood, patients with potentially modified patterns, ... 510(L)
Dombrock blood group system, ... 1022, 1026
D-positive cell, maternal weak D variant, ... 177
Drug-induced deficiency, antithrombin III, ... 481
Duffy blood group locus, allele-specific primer polymerase chain reaction, ... 118(E)
Duffy (Fy) blood group system
allele-specific primer polymerase chain reaction, ... 168
ethnic population, ... 168
Dura mater graft, ... 312

E

E2 protein antibody, ... 290
Effectiveness of quality improvement efforts, ... 999(E), 1030, 1071
Eindhoven Classification Model (Medical Version), ... 999(E), 1071
Elastase
delayed hemolytic transfusion reaction, ... 459
systemic inflammatory response syndrome mediator, ... 459
Emergency transfusion of red cells without irradiation in Japan, ... 1117(L)
Encephalo-myocarditis virus, dimethylmethylene blue, ... 729
Endothelial injury, thrombotic thrombocytopenic purpura, ... 419
Endotoxin, transfusion-associated sepsis, ... 703(L)
Enrichment of CD34+ cells by immunomagnetic selection, ... 1063
Enterococcus faecalis, ... 1090
Enzyme immunoassay
hepatitis B surface antigen mutant form, ... 56
hepatitis C virus, ... 194
human immunodeficiency virus-2, ... 189
Enzyme-linked antiglobulin test, ... 252
Enzyme-linked immunosorbent assay
cytotoxic white cell antibody, ... 41
HLA antibody identification, ... 41
HLA antibody screening, ... 41
HLA-A locus specificity, ... 41
HLA-B locus specificity, ... 41
IgG anti-D
alloimmunized patients, ... 252
quantitation, ... 252
IgG subclass
alloimmunized patients, ... 252
quantitation, ... 252
immunohematology, ... 41
non-complement-fixing HLA antibody, ... 41
nonspecific hemagglutination, ... 41
red cell-bound immunoprotein, ... 782
thrombopoietin, ... 449
Enzyme-only blood group alloantibody, pregnancy, ... 318(L)
Error reporting systems, ... 999(E), 1030, 1071
Erythropoiesis, autologous blood donation, compensatory erythropoiesis, ... 613(L)
Erythropoietin, preoperative autologous blood donation, ... 400
Escherichia coli, ... 674, 1090
Ethical issues, cord blood banking
conference report, ... 867
workshop summary, ... 867
Ethnic population
allele-specific primer polymerase chain reaction, ... 168
Duffy (Fy) blood group system, ... 168
FY glycoprotein, ... 168
Ethyl palmitate, ... 550
European Acute Transfusion-associated Hepatitis Interferon Study, ... 194
European Medicines Evaluation Agency, Committee for Proprietary Medicinal Products, ... 506(L)
Exchange transfusion
delayed hemolytic transfusion reaction, ... 459
systemic inflammatory response syndrome mediator, ... 459
Expansion of CD34+ cells, ... 1063
Exponetially decreaseing theoretical distribution, in reporting blood usage, ... 12, 1119(L)
Extent of shape change test
dimethyl sulfoxide, ... 160
platelet
accuracy, ... 31
multi-laboratory evaluation, ... 31
reproducibility, ... 31
sensitivity, ... 31
second messenger effector mixture, ... 160
Extracorporeal circuit, antithrombin III, ... 481

F

Factor IX concentrate, hepatitis A virus, ... 573
Factor VIII
hepatitis A virus, ... 573
transmissible spongiform encephalopathy, ... 810
Factors in errors in transfusion, ... 999(E), 1030, 1071
Fas and Fas ligand, role in white cell apoptosis, ... 1082
Fcγ receptor IIA polymorphism, ... 174
allele-specific primer polymerase chain reaction, ... 174
DNA-based genotyping method, ... 174
functional phagocytosis assay, ... 174
Fcγ receptor polymorphism, immunohematology, ... 174
FcγRIIa receptor, allele-specific primer polymerase chain reaction, ... 118(E)
Febrile neutropenia, ... 209
granulocyte, ... 557
Febrile nonhemolytic transfusion reaction
apoptosis as cause, ... 1082
cytokine, ... 236
duration of platelet storage, ... 229
lymphocytotoxic antibody, ... 229
Feedback (detectability of error), ... 999(E), 1071
Fetomaternal hemorrhage, ... 749
gel agglutination technique, ... 177
immunohematology, ... 177
screening, ... 177
Fetus
A antigen, ... 975
B antigen, ... 975
fetal cell detection, in maternal blood samples, ... 749
fetal hemoglobin, ... 749
fetal hemoglobin monoclonal antibody, flow cytometry, ... 749
Fibrin deposition by platelet substitute, ... 997(E), 1004
Fibrinogen
delayed hemolytic transfusion reaction, ... 459
systemic inflammatory response syndrome mediator, ... 459
Fifth disease, ... 108(L)
Filgrastin. *See* Granulocyte—colony-stimulating factor
Filtration
blood component, ... 16
C5a, ... 16
interleukin 8, ... 16
leukotriene B4, ... 16
platelet concentrate, ... 16
tumor necrosis factor alpha, ... 16
white cell reduction, ... 317(L)
FK-506, ... 225(E)
Flow cytofluorometry, red cell-bound immunoprotein, ... 782
Flow cytometry, ... 262
detection of white cell apoptosis in stored red cells, ... 1082
fetal hemoglobin monoclonal antibody, detection of fetal

red cells in fetomaternal hemorrhage, ... 749
platelet, fresh human platelets in rabbit model, ... 550
p-selectin, ... 24
Fluoflow cytometry, white cell-reduced platelet concentrate, ... 650
Fluorescence microscopy, platelet, ... 550
Food and Drug Administration
blood bank software
current regulation status, ... 86
internationally developed software, ... 86
regulation, ... 86
regulation future, ... 86
regulation history, ... 86
Blood Products Advisory Committee, ... 102
error (event) reporting system, ... 999(E), 1030, 1071
Forward ABO group
AutoVue System, ... 959
column agglutination technology, ... 959
pretransfusion testing instrument, ... 959
Fraction I+II+III, transmissible spongiform encephalopathy, ... 810
Fraction IV, transmissible spongiform encephalopathy, ... 810
Fraction V, transmissible spongiform encephalopathy, ... 810
France
bedside blood grouping, ... 999(E), 1030
mandatory hemovigilance system, ... 999(E), 1030, 1071
nucleic acid testing, ... 989
Frequency distributions in reporting blood usage, ... 12, 1119(L)
Fresenius AS104 apheresis machine, peripheral blood progenitor cell collection
CD34+ cell enrichment, ... 70
CD34+ cell extraction, ... 70
CD34 cytofluorimetry, ... 70
extraction efficiency, ... 70
mononuclear cell purity, ... 70
platelet count decreases, ... 70
red cell contamination, ... 70
Fresh-frozen plasma, ... 102
irradiation, ... 645
white cell
fast filtration, ... 645
filter capacity, ... 645
flow cytometry, ... 645
hard-spin method, ... 645
second-spin method, ... 645
slow filtration, ... 645
soft-spin method, ... 645
white cell-reduction filter
fast filtration, ... 645
filter capacity, ... 645
flow cytometry, ... 645
second-spin methods, ... 645
slow filtration, ... 645
soft-spin methods, ... 645
Fulminant Wilson's disease, copper, ... 327
Functional phagocytosis assay, *Fcγ receptor IIA* polymorphism, ... 174
FY glycoprotein
allele-specific primer polymerase chain reaction, ... 168
ethnic population, ... 168
molecular basis of the three major alleles, ... 168

G

G1006T (Gly336Cys) polymorphism
allele-specific polymerase chain reaction, ... 951
polymerase chain reaction, ... 951
GB agent, blood donor
infectivity, ... 290
prevalence, ... 290
volunteer blood donors in Taiwan, ... 290
GB virus type C
alanine aminotransferase, ... 378
anti-E2 enzyme-linked immunosorbent assay, ... 821
Australia, ... 821
children, ... 821
evidence of past infection, ... 821
hemodialysis, ... 821
hemophilia, ... 821
hepatitis C antibody-positive donor, ... 821
injecting drug user, ... 821
polymerase chain reaction, ... 378
pregnant women, ... 821
reverse transcriptase polymerase chain reaction, ... 821
Sweden, ... 378
testing for current infection, ... 821
Gel agglutination technique
anti-D, ... 177
D-negative cell, ... 177
D-positive cell, ... 177
fetomaternal hemorrhage, ... 177
immunohematology, ... 177
Kleihauer-Betke test, compared, ... 177
Rh immune globulin, ... 177
Gender
p-selectin, ... 24
transfusion practice, ... 392
allogeneic transfusion in cardiac surgery, ... 392
allogeneic transfusion in orthopedic surgery, ... 392
cryoprecipitate, ... 392
fresh-frozen plasma, ... 392
intraoperative hypothermia, ... 392
platelets, ... 392
preoperative autologous blood donation, ... 392
Gene therapy, ... 1063
General health, of donors positive for human T-lymphotropic virus, ... 1056
General Well-Being Scale, ... 1056
Genotyping, in Rh blood group system, ... 1015
Glucose, red cell, 24-hour storage at 25°C, ... 424
Glutaraldehyde, ... 429
Gly_{565}→Ala substitution in human erythroid band 3, Wu blood group polymorphism, ... 745
Glycophorin A
M-allele, ... 658
N-allele, ... 658
Glycoprotein Ia/II receptors, ... 997(E), 1004
Glyocprotein IIb/IIIa receptors, ... 997(E), 1004
Glycoprotein Ib receptor, ... 997(E), 1004
Glycoprotein IX, ... 550
Good Manufacturing Practice, collection of peripheral blood stem and progenitor cells, ... 1051
Graft-*versus*-host disease
prevention of by irradiation or storage of red cells for more than 7 days in Japan, ... 1118(L)
prophylaxis, ... 247
reporting of, ... 999(E), 1030, 1071
Granulocyte, ... 650
apoptosis in stored red cells,
CD34+ cell, time to engraftment, ... 385
chemotherapy, ... 722
continuous-flow blood cell separator, ... 557
count as predictor of CD34+ cell collection efficiency, ... 1046
febrile neutropenia, ... 557
future transfusion directions, ... 710(E)
granulocyte—colony-stimulating factor, ... 663, 722, 1051, 1063
neutrophil cell dose, ... 557
prednisone
comparison, ... 722
evaluation, ... 722
mobilization schedules, ... 722
white cell counts, ... 722
Granulocyte—colony-stimulating factor, ... 1, 710(E)
apheresis
enrichment of CD34+ cells, ... 1063
granulocyte collection efficiency, ... 557, 1051
granulocyte collection yield, ... 557
hematocrit, ... 557
higher interface offset, ... 557
platelet count, ... 557, 1051
red cell volume, ... 557

CD11a, 663
CD11b, 663
CD13, 663
CD14, 663
CD16, 663
CD18, 663
CD32, 663
CD34+ cell selection, 60
CD62L, 663
CD64, 663
granulocyte, 663
comparison, 722
evaluation, 722
mobilization schedules, 722
white cell counts, 722
multiple daily doses, 663
neutrophil
adverse effects, 713
bactericidal activity, 713
CD11b, 713
CD14, 713
CD18, 713
CD32, 713
CD64, 713
chemiluminescence, 713
functions, 713
immunophenotype analysis, 713
kinetics, 713
morphology, 713
neutrophil antigen, after 10 days, 663
neutrophil-specific antigen NB1, 663
peripheral blood progenitor cell
CD34+ cell collection, 209, 1046, 1051
costs of mobilization, 209
engraftment, 209
Granulocyte-macrophage—colony-stimulating factor, peripheral blood progenitor cell
CD34+ cell collection, 209
costs of mobilization, 209
engraftment, 209
Granulocyte-macrophage—CSF, 1
Group A, Jk(b+), 247
Group O, Jk(b-), 247
Group O apheresis platelet, 51
Group O R_1R_2 red cell, 252
Growth hormone, 312

H

Haemonetics MCS 3P apheresis machine, peripheral blood progenitor cell collection
CD34+ cell enrichment, 70
CD34+ cell extraction, 70
CD34 cytofluorimetry, 70
extraction efficiency, 70
mononuclear cell purity, 70
platelet count decreases, 70
red cell contamination, 70
Health status indicators in donors who are positive for human T-lymphotropic virus, 1056
Heart transplant, ABO incompatibility, 975
Hemagglutination, 332
IgG subclass, 252
Hemagglutination inhibition
Cromer blood group antibody, soluble recombinant decay-acelerating factor, 332
immunohematology, 332
Hemagglutination-inhibition assay, 658
Hematocrit
as indicator of red cell volume deficit, 602
as predictor of CD34+ cell collection efficiency, 1046
perioperative myocardial ischemic episode, 924
prostatectomy, 924
tachycardia, 924
transfusion practice, 924
Hematologic disease, effect on bleeding time, activated partial thromboplasin time, and prothrombin time, 1011
Hematologic malignancy, transforming growth factor β_1, after transfusion of platelet concentrates, 156
Hematopoietic progenitor cell transplantation, platelet transfusion, 839
clinical factors influencing posttransfusion platelet increment, 839
HLA antibodies with restricted specificity, 839
platelet antibodies, 839
posttransfusion (16-hour) corrected count increments, 839
serum cyclosporin A, 839
serum tacrolimus, 839
total bilirubin, 839
total body irradiation, 839
Hematopoietic stem cell component
collection, 1046, 1051, 1063
processing, 1(E), 1063
transplantation, 1(E)
Hemodialysis
GB virus type C, 821
hepatitis E virus antibody, 589
hepatitis G virus, 821
Hemodilution
intravenous perfluorocarbon emulsion, 135
left ventricular pressure-volume relationship, 135
myocardial contractility, 135
organ tissue oxygenation, 135
perflubron, 135
systemic oxygenation, 135
tissue oxygenation, 145
transfusion practice, 135, 145
Hemoglobin
ABO-incompatible plasma, 51
apheresis platelet, 51
blood donor
additional donations, 855
female plateletpheresis donors, 855
frequency of donor reactions, 855
hemoglobin cutoff of 12.5 g per dL, 855
standards of the American Association of Blood Banks, 855
fetal, 749
as indicator of red cell volume deficit, 602
iron supplementation, 764
red cell transfusion, 522
red cell-bound immunoprotein, 782
Hemoglobin F, hereditary persistence, 177
Hemolysis
ABO incompatibility, 51, 999(E), 1030, 1071
delayed hemolytic transfusion reaction, 459, 1022, 1026
mechanisms in sickle cell disease, 1022, 1026
plasma-incompatible apheresis platelet, 51
systemic inflammatory response syndrome mediator, 459
transplantation, 224(E)
ABO-incompatible allogeneic marrow transplant, 225(E)
autoimmune hemolytic anemia, 225(E)
bystander immune hemolysis, 225(E)
Clostridium perfringens, 225(E)
drug administration, 225(E)
hemolytic-uremic syndrome, 225(E)
major ABO blood group incompatibility, 225(E)
minor ABO-incompatible allotransplantation, 224(E)
passenger lymphocyte syndrome, 224(E)
passive transfer of antibody, 225(E)
solid organ, 225(E)
thrombotic thrombocytopenic purpura, 225(E)
Hemolytic anemia, 327
Hemolytic disease of newborn, 252, 749
Hemolytic transfusion reaction
ABO incompatibility, 51, 999(E), 1030, 1071
anti-Do^a, 1022, 1026
anti-Do^b, 1022, 1026
anti-P_1, 373
plasma-incompatible apheresis platelet, 51
Hemolytic-uremic syndrome, 225(E)

plasma exchange, ... 834
Hemophilia
Creutzfeldt-Jakob disease
formalin-fixed paraffin block brain samples, ... 817
prion, ... 817
surveillance, ... 817
GB virus type C, ... 821
hepatitis C virus, Turkey, ... 798(L)
hepatitis G virus, ... 821
Hemorrhage, acute preoperative normovolemic hemodilution
hyperoxic ventilation, ... 135
management, ... 135
Hemostasis, red cell transfusion, ... 602
Hemostatic process, platelets, ... 997(E), 1004
Hemovigilance, ... 999(E), 1030, 1071
Heparin resistance, antithrombin III, ... 481
Hepatic failure, ... 327
Hepatitis A virus
clotting factor concentrate, ... 573
common source-plasma pool, ... 573
factor IX concentrate, ... 573
factor VIII concentrate, ... 573
seroprevalence study, ... 573
solvent/detergent-treated antihemophilic factor VIII concentrate, ... 573
Hepatitis *B e* antigen, hepatitis B surface antigen mutant form, ... 56
Hepatitis B surface antigen mutant form
antibody to hepatitis B core antigen, ... 56
antibody to hepatitis *B e* antigen, ... 56
enzyme immunoassay, ... 56
hepatitis *B e* antigen, ... 56
hepatitis B virus DNA, ... 56
radioimmunoassay, ... 56
screening assay, ... 56
Hepatitis B surface antigen screening assay, hepatitis B virus mutant form, ... 56
undetectability, ... 56
Hepatitis B virus
envelope mutant forms, ... 56
no-fault compensation, ... 596
Italian experience, ... 596
nucleic acid testing, results using mini-pools, ... 905
Hepatitis B virus DNA
hepatitis B surface antigen mutant form, ... 56
screening, ... 56
Hepatitis B virus mutant form
DNA sequence analysis, ... 56
hepatitis B surface antigen screening assay, ... 56
undetectability, ... 56
transfusion complication, ... 56
Hepatitis C antibody-positive donor
GB virus type C, ... 821
hepatitis G virus, ... 821
Hepatitis C virus
alanine aminotransferase, ... 378, 1097
blood donor, ... 512(L)
Canada, ... 316(L)
enzyme immunoassay, ... 194
hemophilia, Turkey, ... 798(L)
HIV-1 RNA, concomitant detection, ... 908
no-fault compensation, ... 596
Italian experience, ... 596
nucleic acid testing, results using mini-pools, ... 905
polymerase chain reaction, ... 194, 378
plasma pools, ... 908
plasma sample pools, ... 915
polyethylene glycol precipitation step, ... 908
preseroconversion window period, ... 908
sensitivity, ... 908
specificity, ... 908
recombinant immunoblot assay, ... 194
single-antigen research immunoassay, ... 194
superoxide dismutase, ... 194
Sweden, ... 378
Hepatitis E virus, ... 589
Hepatitis E virus antibody
chronic viral hepatitis, ... 589
hemodialysis, ... 589
increased prevalence in hemodialysis unit, ... 589
injecting drug user, ... 589
multiply transfused patient, ... 589
Hepatitis G virus
alanine aminotransferase, ... 378, 1097
angioedema, ... 307
anti-E2 enzyme-linked immunosorbent assay, ... 821, 1097
Australia, ... 821
blood donor
infectivity, ... 290
prevalence, ... 290
volunteer blood donors in Taiwan, ... 290
children, ... 821
complement component 1 inhibitor deficiency
enzyme-linked immunosorbent assay, ... 307
nested polymerase chain reaction, ... 307
steam-heated plasma concentrates of C1 inhibitor, ... 307
evidence of past infection, ... 821
France, ... 1097
hemodialysis, ... 821
hemophilia, ... 821
hepatitis C antibody-positive donor, ... 821
injecting drug user, ... 821
polymerase chain reaction, ... 378, 1097
pregnant women, ... 821
reverse transcriptase polymerase chain reaction, ... 821
Sweden, ... 378
testing for current infection, ... 821
thalassemia
genetic heterogeneity, ... 301
immunity to hepatitis G/GB-C virus, ... 301
multiply transfused patients, ... 301
NS3 gene, ... 301
reverse transcriptase-polymerase chain reaction assay, ... 301
sequence analysis, ... 301
viremia, ... 301
transfusion complication, ... 301, 307, 1097
Hepatitis G virus/GB virus-C, ... 506(L)
Hepatocellular necrosis, ... 327
Hereditary angioedema, C1 inhibitor concentrate
efficacy, ... 540
randomized controlled trial, ... 540
recovery of antigenic C1 inhibitor, ... 540
recovery of functional C1 inhibitor, ... 540
resolution of symptoms, ... 540
safety, ... 540
time-to-relief, ... 540
High-dose chemotherapy, platelet survival, ... 637
High-titer low-avidity antibody, interference with red cell antibody screening, ... 1022,1026
Hip arthroplasty, transfusion practice, ... 738
autologous blood conservation strategies, ... 738
number of red cell units, ... 738
perioperative red cell units, ... 738
postoperative red cell units, ... 738
timing of transfusion, ... 738
Hip fracture, red cell transfusion
indications for transfusion, ... 522
randomized trial comparing symptomatic *vs.* hemoglobin-level-driven, ... 522
Hip replacement, blood transfusion, prospective validation of point score system for predicting, ... 932
Hip surgery. *See also* Specific type
autologous blood donation, interhospital variations, ... 530
red cell transfusion, interhospital variations, ... 530
Histo-blood group ABO system, tissue transplantation, ... 975
HLA antibody
identification/screening, enzyme-linked immunosorbent assay, .. 41

interference in red cell antibody detection, ... 1022, 1026
HLA antibody screening, enzyme-linked immunosorbent assay, .. 41
HLA typing, allele-specific polymerase chain reaction, ... 118(E)
HLA-A locus specificity, enzyme-linked immunosorbent assay, ... 41
HLA-B locus specificity, enzyme-linked immunosorbent assay, ... 41
HLA-DQ-A polymerase chain reaction quantitation, ... 262
HLA-DQ-A sequence, ... 262
Home health care, home transfusion, ... 90
Home health care agency, home transfusion
informed consent, ... 90
patient diagnosis, ... 90
posttransfusion visit, ... 90
transfusionists, ... 90
written policies, ... 90
Home transfusion
administration, nationwide survey, ... 90
American Association of Blood Banks institutional member
component issued, ... 90
informed consent, ... 90
patient diagnosis, ... 90
posttransfusion visit, ... 90
transfusionists, ... 90
written policies, ... 90
home health care, ... 90
home health care agency
informed consent, ... 90
patient diagnosis, ... 90
posttransfusion visit, ... 90
transfusionists, ... 90
written policies, ... 90
Human albumin
bacterial infection, ... 690
in biologic therapeutic products, ... 690
Creutzfeldt-Jakob disease, ... 690
prion, ... 690
risk-reduction steps in production, ... 690
safety, research, ... 690
transmission of viral infection, ... 690
virus-inactivation procedures, ... 690
virus-neutralizing antibody, ... 690
Human error classifications, ... 999(E), 1071
Human herpesvirus 8
Central Africa, prevalence, ... 771
nested polymerase chain reaction, ... 771
peripheral blood mononuclear cell, ... 771
Human immunodeficiency virus
blood donor
donor selection criteria identification, ... 279
exclusion strategy, ... 279
risk factors in first-time blood donors in Zimbabwe, ... 279
self-administered survey, ... 279
immunoblot assay, ... 776
enzyme immunoassay, ... 776
sensitivity, ... 776
specificity, ... 776
validation, ... 776
LiaTek human immunodeficiency virus III, ... 776
enzyme immunoassay, ... 776
sensitivity, ... 776
specificity, ... 776
validation, ... 776
no-fault compensation for infection, ... 596
Italian experience, ... 596
nucleic acid testing, results using mini-pools, ... 905
Human immunodeficiency virus type-1
cell-free plasma
after storage, ... 580
compartmentalization of human immunodeficiency virus-1, ... 580
immediately after component preparation, ... 580
distribution in blood components, ... 580
peptide enzyme immunoassay, ... 189
peripheral blood mononuclear cell
after storage, ... 580
compartmentalization of human immunodeficiency virus-1, ... 580
immediately after component preparation, ... 580
platelet
detection, ... 580
significance, ... 580
white cell-reduced platelet concentrate
after storage, ... 580
compartmentalization of human immunodeficiency virus-1, ... 580
immediately after component preparation, ... 580
white cell-reduced red cell
after storage, ... 580
compartmentalization of human immunodeficiency virus-1, ... 580
immediately after component preparation, ... 580
Human immunodeficiency virus type-1 p24 antigen, ... 469
Human immunodeficience virus type-1 RNA
hepatitis C virus, concomitant detection, ... 908
polymerase chain reaction
plasma pools, ... 908
polyethylene glycol precipitation step, ... 908
preseroconversion window period, ... 908
sensitivity, ... 908
specificity, ... 908
Human immunodeficiency virus type-1 RNA genome amplification
individual-unit testing, ... 469
pooled plasma testing, effects of dilution, ... 469
Human immunodeficiency virus-1 Western blot, human immunodeficiency virus-2, ... 189
Human immunodeficiency virus-1/human immunodeficiency virus-2 enzyme immunoassay, human immunodeficiency virus-2, ... 189
Human immunodeficiency virus-2
enzyme immunoassay, ... 189
human immunodeficiency virus-1 Western blot, ... 189
human immunodeficiency virus-1/human immunodeficiency virus-2 enzyme immunoassay, ... 189
peptide enzyme immunoassay, ... 189
transfusion complication, ... 189
Western blot, ... 189
whole-virus lysate enzyme immunoassay, ... 189
Human immunodeficiency virus-2 antibody-positive blood donor
characterization, ... 189
identification, ... 189
Human parvovirus B19 DNA, receptor-mediated hemagglutination assay, ... 108(L)
Human T-cell lymphotropic virus type I, white cell reduction
Tax proviral sequence, ... 317(L)
Tax-encoded protein, ... 317(L)
Human T-lymphotropic virus-associated myelopathy, .. 1056, 1118(L)
Human T-lymphotropic virus type I
Africa, in 1969, ... 612(L)
Japan, prior to the 1980s, ... 612(L)
notification of donors positive for, ... 1056
origins, ... 612(L)
prevalence in donors in Taiwan, ... 1118(L)
psychological stress in donors positive for, ... 1056
Human T-lymphotropic virus type I *tax* sequence, United States, ... 800(L)
Human T-lymphotropic virus type II
Africa, in 1969, ... 612(L)
notification of donors positive for, ... 1056
origins, ... 612(L)
psychological stress in donors positive for, ... 1056
Hypercupremic patient, ... 327
Hyperoxic ventilation
intravenous perfluorocarbon emulsion, ... 135
left ventricular pressure-volume relationship, ... 135
myocardial contractility, ... 135
organ tissue oxygenation, ... 135
perflubron, ... 135
systemic oxygenation, ... 135
transfusion practice, ... 135
Hypotensive reaction
angiotensin-converting enzyme inhibitor, ... 410(L)
red cells filtered at the bedside, ... 410(L)
red cells filtered before storage, ... 410(L)
kallikrein-kinin cascade, ... 410(L)

platelet transfusion, ... 410(L)
white cell-reduced apheresis platelet concentrates, ... 410(L)
white cell-reduction filter, ... 410(L)
Hypotonic shock response
dimethyl sulfoxide, ... 160
second messenger effector mixture, ... 160
Hypotonic shock response test, platelet
accuracy, ... 31
multi-laboratory evaluation, ... 31
reproducibility, ... 31
sensitivity, ... 31

I

Iceberg model, ... 999(E), 1071
Identification of error in transfusion medicine, ... 999(E), 1071
IgG anti-A, ... 247
IgG anti-D
enzyme-linked immunosorbent assay
alloimmunized patients, ... 252
quantitation, ... 252
immunohematology, ... 252
IgG subclass
enzyme-linked immunosorbent assay
alloimmunized patients, ... 252
quantitation, ... 252
hemagglutination, ... 252
immunohematology, ... 252
IgM
anti-P_1, ... 373
monoclonal reagents in column agglutination technology for red cell phenotyping, ... 1037
Immediate-spin crossmatch, ... 343
Immune hemolytic anemia
bone marrow transplant
ABO-incompatible allogeneic, ... 247
multiple red cell alloantibodies, ... 247
immunohematology, ... 247
Immune-mediated thrombocytopenia, ... 97
Immune response to cryptic nuclear antigens exposed by apoptosis in stored red cells, ... 1082
Immunoblot assay, human immunodeficiency virus, ... 776
enzyme immunoassay, ... 776
sensitivity, ... 776
specificity, ... 776
validation, ... 776
Immunoglobulin light-chain variable region genes, CD34+ cell selection, ... 60
Immunohematology
allele-specific primer polymerase chain reaction, ... 168
anti-D, ... 565
automated pretransfusion testing, ... 959
*cis*AB blood type, ... 441
enzyme-linked immunosorbent assay, ... 41
Fcγ receptor polymorphism, ... 174
fetal hemoglobin monoclonal antibody, ... 749
fetomaternal hemorrhage, ... 177
gel agglutination technique, ... 177
granulocyte—colony-stimulating factor, ... 663
hemagglutination inhibition, ... 332
IgG anti-D, ... 252
IgG subclass, ... 252
immune hemolytic anemia, ... 247
non-complement-fixing HLA antibody, ... 41
plasma membrane vesicles expressing recombinant glycophorin A-encoded blood group antigens, ... 658
pretransfusion testing, ... 343
quantitation using frozen whole blood, ... 262
reticulocyte immunophenotyping, ... 337
RHD genotyping, ... 434
V polymorphism, ... 951
VS polymorphism, ... 951
Immunologic activity of lymphocytes after storage in red cells, ... 1117(L)
Immunomagnetic selection of CD34+ cells, ... 1063
In vitro platelet assay
blood component, ... 31
multi-laboratory evaluation, ... 31
Indirect antiglobulin test, ... 252
anti-P_1, ... 373
nonspecific hemagglutination, ... 41
Indirect monocyte monolayer assay, anti-P_1, ... 373
Individual-unit testing, human immunodeficiency virus-1 RNA genome amplification, ... 469
Inexperience, nurses and bedside compatibility test errors, ... 999(E), 1030
Infrequent transfusion activity and bedside compatibility test errors, ... 999(E), 1030
Injecting drug user
GB virus type C, ... 821
hepatitis E virus antibody, ... 589
hepatitis G virus, ... 821
Interagency Genome Amplification Testing Task Force, preliminary report, ... 903(E)
Interleukin-1
delayed hemolytic transfusion reaction, ... 459
systemic inflammatory response syndrome mediator, ... 459
Interleukin-1β, white cell reduction, ... 236
Interleukin-2, white cell reduction, ... 236
Interleukin-6
delayed hemolytic transfusion reaction, ... 459
systemic inflammatory response syndrome mediator, ... 459
white cell reduction, ... 236
Interleukin-8
delayed hemolytic transfusion reaction, ... 459
filtration, ... 16
storage, ... 16
systemic inflammatory response syndrome mediator, ... 459
white cell reduction, ... 236
Interleukin-10
delayed hemolytic transfusion reaction, ... 459
systemic inflammatory response syndrome mediator, ... 459
International Organization for Standardization. *See* ISO
International Normalized Ratio, ... 1011
Intestinal transplantation, ... 9
Intranasal drug use, blood donor, ... 512(L)
Intraoperative blood recovery technique, ... 400
malignancy, ... 400
washed *vs.* unwashed, ... 400
Intravenous perflubron emulsion
tissue oxygenation, ... 145
transfusion practice, ... 145
Intravenous perfluorocarbon emulsion
hemodilution, ... 135
hyperoxic ventilation, ... 135
Iron supplementation
autologous blood donation, ... 764
intravenous iron, ... 764
oral iron supplementation, ... 764
hemoglobin, ... 764
Irradiation
fresh-frozen plasma, ... 645
prevention of graft-versus-host disease, ... 1117(L)
role in white cell apoptosis, ... 1082
ISO, ... 5(E)
goals, ... 5
history, ... 5
quality assurance model, ... 5
registration, ... 5
ISO 9000 registration
administration, ... 75, 79
benefits and uses, ... 5
blood banking, ... 5
case study, ... 75
characterized, ... 5
consultant, ... 75
countries and regions adopting, ... 5
forces for, ... 5
as foundation for total quality management, ... 5
quality model, ... 79

improvements, ... 79
methods, ... 79
standard operating procedures, ... 79
status of readiness ISO assessment audit (gap analysis), ... 79
US registration information, ... 5
Isolex 300 SA, magnetic-cell separation system, ... 1063
Israel, *cis*AB blood type, ... 441
Italy, no-fault compensation, ... 596

J

Japan
human T-lymphotropic virus type I, prior to the 1980s, ... 612(L)
prevention of graft-versus-host disease, ... 1117(L)
RHD genotyping, ... 434

K

Kallikrein-kinin cascade, hypotensive reaction, ... 410(L)
Kell blood group system, ... 1037
Kidd blood group system, ... 1037
Kleihauer-Betke test, gel agglutination technique, compared, ... 177
Knee arthroplasty, transfusion practice, ... 738
autologous blood conservation strategies, ... 738
number of red cell units, ... 738
perioperative red cell units, ... 738
postoperative red cell units, ... 738
timing of transfusion, ... 738
Knee replacement, blood transfusion, prospective validation of point score system for predicting, ... 932
Knee surgery. *See also* Specific type
autologous blood donation, interhospital variations, ... 530
red cell transfusion, interhospital variations, ... 530
Knowledge, Attitude, Practice (KAP) and Outcome, ... 999(E), 1030, 1071
Knowledge-based behavior or error, ... 999(E), 1071
Kruskal-Wallis test, ... 12, 1119(L)

L

Laboratory equipment, contamination of samples for polymerase chain reaction, ... 1041
Lactate, red cell, 24-hour storage at 25°C, ... 424
Large-volume leukapheresis, ... 1
CD34+ cell selection, ... 60
Latent errors, ... 999(E), 1071
L-Ase therapy, antithrombin III, ... 481
Left ventricular pressure-volume relationship
hemodilution, ... 135
hyperoxic ventilation, ... 135
Leukapheresis
mobilized peripheral blood progenitor cell, combination mobilization regimen, ... 209
pediatric, ... 70
Leukocyte clusters of differentiation
new, ... 499
redefined, ... 499
Leukotriene B4
filtration, ... 16
storage, ... 16
LeVeen peritoneovenous shunt, antithrombin III, ... 481
Lewis blood group system, ... 1037
LiaTek human immunodeficiency virus III, human immunodeficiency virus, ... 776
enzyme immunoassay, ... 776
sensitivity, ... 776
specificity, ... 776
validation, ... 776
Lipid priming agent, lung injury, ... 991(L)
Liposomal preparations, ... 997(E), 1004
Liver dysfunction, antithrombin III, ... 481
Liver transplantation, ... 9
antithrombin III, ... 481
Log-normal distribution, ... 12, 1119(L)
Low-ionic wash solution, commercial acid-elution kit
acid elution, ... 565
antigen-negative red cell, ... 565
D+ red cell, ... 565
D- red cell, ... 565
false-positive eluate reactivity, ... 565
IgG, ... 565
phosphate-buffered saline, ... 565
Low-ionic-strength saline indirect antiglobulin test, ... 318(L)
Lung injury, lipid priming agent, ... 991(L)
Lung transplantation, ... 9
cardiopulmonary bypass, ... 12, 1119(L)
plasma, ... 12
platelet, ... 12
red cell, ... 12
transfusion practice, ... 12, 1119(L)
Lymphocyte
apoptosis in stored red cells, ... 1082
CD34+ cell selection, ... 60
proliferative capacity in stored red cells, ... 1082
reduced immunologic activity after storage in red cells, ... 1117(L)
Lymphocytotoxic antibody
allergic reaction, ... 229
febrile nonhemolytic transfusion reaction, ... 229
Lymphocytotoxicity test, ... 41

M

Magnetic-cell separation system, ... 1063
Mail survey, donor deferral registry, ... 45
Malignancy, intraoperative blood recovery technique, ... 400
Management of errors in transfusion medicine, ... 999(E), 1071
Mann-Whitney test, ... 12, 1119(L)
Marsh, W. Laurence, ... 216
Maternal circulation, level of fetal cells, ... 749
Maximum surgical blood order, ... 12, 1119(L)
MCS 3P apheresis machine, pediatric leukapheresis, ... 71
MCS 3P cell separator, platelet, ... 24
gender, ... 24
p-selectin, ... 24
Mean and standard deviation to describe blood usage, ... 12, 1119(L)
Medical care, gender-related differences, ... 392
Medical Event Reporting System for Transfusion Medicine (MERS-TM), ... 999(E), 1071
Megakaryocytopoiesis, thrombopoietin, ... 449
Mephalan, CD34+ cell selection, ... 60
Method control in polymerase chain reaction, ... 1041
Microchimerism, ... 262, 1041
Microscopic evaluation of white cell apoptosis, ... 1082
Minor ABO incompatibility, ... 51
Mitomycin, ... 225(E)
Monitoring of errors in transfusion medicine, ... 999(E), 1071
Monoclonal antibody, ... 337, 1015, 1063
Monoclonal reagent
ABO testing, ... 343
IgM in column agglutination technology for red cell phenotyping, ... 1037
Monoclonal-polyclonal blended reagent, Rh testing, ... 343
Monocyte, ... 650
Monocyte monolayer assay, ... 1026
Mononuclear cell
count as predictor of CD34+ cell collection efficiency, ... 1046
Orientia tsutsugamushi, ... 680
Multiplex polymerase chain reaction, ... 1015
Multiply transfused patient, hepatitis E virus antibody, ... 589
Murine monoclonal antibody, ... 337
Mutations in Rh blood group system, ... 1015
Myelodysplastic syndrome, anemia in, ... 1011
Myocardial contractility
hemodilution, ... 135
hyperoxic ventilation, ... 135

N

Nageotte hemocytometer, reducing counting area, ... 429
National Blood Data Resource Center, ... 622(E)
Nationwide Blood Collection and Utilization Survey, ... 622(E)
Near-miss event, ... 999(E), 1030, 1071
Neopterin
delayed hemolytic transfusion reaction, ... 459
systemic inflammatory response syndrome mediator, ... 459
Nested polymerase chain reaction, human herpesvirus, ... 8, 771
Neutrophil

CD34+ cell selection, ... 60
dexamethasone
adverse effects, ... 713
bactericidal activity, ... 713
CD11b, ... 713
CD14, ... 713
CD18, ... 713
CD32, ... 713
CD64, ... 713
chemiluminescence, ... 713
functions, ... 713
immunophenotype analysis, ... 713
kinetics, ... 713
morphology, ... 713
engraftment after magnetic-cell separation of CD34+ cells, .. 1063
granulocyte—colony-stimulating factor
adverse effects, ... 713
bactericidal activity, ... 713
CD11b, ... 713
CD14, ... 713
CD18, ... 713
CD32, ... 713
CD64, ... 713
chemiluminescence, ... 713
functions, ... 713
immunophenotype analysis, ... 713
kinetics, ... 713
morphology, ... 713
Neutrophil antigen, granulocyte—colony-stimulating factor, after 10 days, ... 663
Neutrophil cell dose, granulocyte, ... 557
Neutrophil transfusion, future directions, ... 710(E)
Neutrophil-specific antigen NB1, granulocyte—colony-stimulating factor, ... 663
Nitric oxide, anemia, ... 602
No-fault compensation
hepatitis B virus, ... 596
Italian experience, ... 596
hepatitis C virus, ... 596
Italian experience, ... 596
human immunodeficiency virus infection, ... 596
Italian experience, ... 596
No-fault/no-fear environment for error reporting, ... 999(E), 1071
Non-A, non-B hepatitis, ... 589
Non-complement-fixing HLA antibody
enzyme-linked immunosorbent assay, ... 41
immunohematology, ... 41
Non-group O autologous bone marrow transplant
apheresis platelet, ... 51
plasma-incompatible apheresis platelet, ... 51
Nonspecific hemagglutination, enzyme-linked immunosorbent assay, ... 41
Nosocomial infection with hepatitis G virus, ... 1097
Notification, effects on donors who are positive for human T-lymphotropic virus, ... 1056
NS3 gene, ... 301
Nucleic acid analysis, white cell, frozen whole-blood samples, ... 262
Nucleic acid testing
blood component, committee report, ... 989
France, ... 989
hepatitis B virus, results using mini-pools, ... 905
hepatitis C virus, results using mini-pools, ... 905
human immunodeficiency virus, results using mini-pools, ... 905
safety of blood components, ... 989
screening, ... 905
Nurses, performance of bedside compatibility test, ... 999(E), 1030

O

Obituary, Richard E. Rosenfield, MD, ... 1115
Oral contraceptive, antithrombin III, ... 481
Organ tissue oxygenation
hemodilution, ... 135
hyperoxic ventilation, ... 135
Organ transplantation, transfusion support, ... 9(E)
Organizational errors in transfusion medicine, ... 999(E), 1071
Orientia tsutsugamushi
mononuclear cell, ... 680
packed red cell
recovery, ... 680
viability, ... 680
storage, ... 680
glycerolized and frozen at -70°C, ... 680
stored at 4°C, ... 680
Oxygen, red cell transfusion, ... 602

P

Packed red cell
Orientia tsutsugamushi, ... 680
Storage conditions and white cell apoptosis, ... 1082
Paling Perspective Scale, communicating transfusion risk information, ... 184
Paroxysmal nocturnal hemoglobinuria
complement-mediated lysis of red cells, ... 337
reticulocyte immunophenotyping, ... 337
Passenger lymphocyte syndrome, ... 224(E)
Pediatric peripheral blood progenitor cell collection, ... 70
Peptide enzyme immunoassay
human immunodeficiency virus-1, ... 189
human immunodeficiency virus-2, ... 189
Percent of discoid cells
dimethyl sulfoxide, ... 160
second messenger effector mixture, ... 160
Perflubron
hemodilution, ... 135
hyperoxic ventilation, ... 135
tissue oxygenation, ... 145
transfusion practice, ... 145
Perfusion models, ... 997(E), 1004
Periodontal abscess, thrombotic thrombocytopenia, ... 419
Perioperative autologous blood donation, redefined, ... 473
Perioperative blood conservation
anemia, ... 924
prostatectomy, ... 924
Perioperative blood recovery, ... 400
Perioperative myocardial ischemic episode, hematocrit, ... 924
Peripheral blood, DNA typing, patients with potentially modified patterns, ... 510(L)
Peripheral blood mononuclear cell
as predictor of CD34+ cell collection efficiency, ... 1046
cytomegalovirus DNA, ... 271
polymerase chain reaction, ... 271
seronegative carriers, ... 271
seronegative donors, ... 271
seropositive donors, ... 271
human herpesvirus 8, ... 771
human immunodeficiency virus-1
after storage, ... 580
compartmentalization of human immunodeficiency virus-1, ... 580
immediately after component preparation, ... 580
Peripheral blood progenitor cell
COBE Spectra apheresis machine, ... 70, 1051
CD34+ cell extraction, ... 70
CD34 cytofluorimetry, ... 70
comparison of AutoPBSC and Version 4.7, ... 1051
extraction efficiency, ... 70
mononuclear cell purity, ... 70
platelet count decreases, ... 70, 1051
red cell contamination, ... 70, 1051
combination mobilization regimen, ... 209
CS300 Plus, collection of CD34+ cells, ... 1046
cyclophosphamide
CD34+ cell collection, ... 209
costs of mobilization, ... 209
engraftment, ... 209
false-positive results for bacterial contamination in BacT/Alert system, ... 1090
Fresenius AS104 apheresis machine
CD34+ cell enrichment, ... 70
CD34+ cell extraction, ... 70

CD34 cytofluorimetry, ... 70
extraction efficiency, ... 70
mononuclear cell purity, ... 70
platelet count decreases, ... 70
red cell contamination, ... 70
granulocyte—colony-stimulating factor
CD34+ cell collection, ... 209, 1046, 1051, 1063
costs of mobilization, ... 209
engraftment, ... 209
granulocyte-macrophage—colony-stimulating factor
CD34+ cell collection, ... 209
costs of mobilization, ... 209
engraftment, ... 209
Haemonetics MCS 3P apheresis machine
CD34+ cell enrichment, ... 70
CD34+ cell extraction, ... 70
CD34 cytofluorimetry, ... 70
extraction efficiency, ... 70
mononuclear cell purity, ... 70
platelet count decreases, ... 70
red cell contamination, ... 70
magnetic separation system, ... 1063
mobilization technique, ... 209
transplantation, pediatric, ... 70
Peripheral blood progenitor cell transplantation, CD34+ cell
autologous, ... 385
colony-forming units—granulocyte macrophage, ... 385
cutoff value, ... 385
engraftment, ... 385, 1063
leukapheresis, ... 385
mononuclear cell, ... 385, 1046
threshold, ... 385
white cell count, ... 385, 1046
Peripheral blood stem and progenitor cell, CD34+ cell selection, ... 199, 1063
Peripheral blood stem cell, ... 1
apheresis
age-specific intra-apheresis recruitment, ... 944
CD34+ cell, ... 944
chemotherapy, ... 944
collection efficiency, ... 944, 1046, 1051, 1063
colony-forming units—granulocyte-macrophage, .. 944, 1063
granulocyte—colony-stimulating factor, ... 944,1046,1051,1063
optimal duration, ... 944
Peripheral blood volume, red cell transfusion, ... 602
Petrochemical industry, comparison of errors in transfusion medicine, ... 999(E), 1071
Phenothiazine derivative
dimethylmethylene blue, ... 729
red cell potassium efflux, ... 729
Phenotype
AutoVue System, ... 959
column agglutination technology, ... 959
reticulocytes, ... 337
Philadelphia chromosome, ... 247
Phosphatidylcholine, ... 997(E), 1004
Phosphatidylethanolamine, ... 997(E), 1004
Phosphatidylinositol, ... 997(E), 1004
Phosphatidyl-L-serine, ... 997(E), 1004
Pichia pastoris, ... 332
Plasma, lung transplantation, ... 12, 1119(L)
Plasma derivative, transmissible spongiform encephalopathy, distribution of infectivity, ... 810
Plasma exchange
albumin, ... 834
copper, ... 327
hemolytic uremic syndrome, ... 834
plasma as replacement fluid, ... 834
indications, ... 834
thrombotic thrombocytopenic purpura, ... 834
occult infection, ... 419
transfusion practice, occult infection, ... 419
Plasma membrane vesicle, recombinant glycophorin A blood group antigen, ... 658
anti-M antibody, ... 658
Plasma volume
CP2D
aggregation, ... 242
glucose, ... 242
hypotonic shock response, ... 242
lactate, ... 242
morphology, ... 242
pCO_2, ... 242
pH, ... 242
pO_2, ... 242
red cell transfusion, ... 602
reduction after CP2D, ... 242
Plasma-incompatible apheresis platelet
acute hemolysis, ... 51
hemolytic transfusion reaction, ... 51
non-group O autologous bone marrow transplant, ... 51
Platelet
apheresis, p-selectin, ... 24
CD34+ cell, time to engraftment, ... 385
CD34+ cell selection, ... 60
coagulation, ... 550
CS 3000 Plus cell separator, ... 24
gender, ... 24
p-selectin, ... 24
discoid shape, ... 31
engraftment after CD34+ cell transplant, ... 1063
extent of shape change test
accuracy, ... 31
multi-laboratory evaluation, ... 31
reproducibility, ... 31
sensitivity, ... 31
flow cytometry, fresh human platelets in rabbit model, ... 550
fluorescence microscopy, ... 550
human immunodeficiency virus-1
detection, ... 580
significance, ... 580
hypotonic shock response test
accuracy, ... 31
multi-laboratory evaluation, ... 31
reproducibility, ... 31
sensitivity, ... 31
initial activation, ... 24
loss after apheresis for peripheral blood stem and progenitor cells, ... 1051
lung transplantation, ... 12, 1119(L)
MCS 3P cell separator, ... 24
gender, ... 24
p-selectin, ... 24
storage, ... 31
CP2D, ... 242
cryopreservation, ... 160
development of transfusion reactions, ... 229
duration, ... 229
long-term, ... 550
plasma volume reduction, ... 242
second messenger effector mixture, ... 160
transforming growth factor beta1, ... 156
virus inactivation, ... 580
in vitro assays, ... 31
Platelet activation
coagulation function, ... 997(E), 1004
interval between plateletpheresis procedures, ... 319(L)/515(L)
Platelet adherence, ... 997(E), 1004
Platelet aggregation
coagulation function, ... 997(E), 1004
thrombotic thrombocytopenic purpura, ... 419
Platelet circulation, ... 997(E), 1004
Platelet collection
Amicus blood cell separator, ... 285
component quality, ... 285
platelet yield, ... 285
separation efficiency, ... 285
white cell contamination, ... 285

AS.TEC 204 blood cell separator, ... 285
component quality, ... 285
platelet yield, ... 285
separation efficiency, ... 285
white cell contamination, ... 285
Platelet component, bacteria, automated microbiologic blood culture device, ... 674/898
Platelet concentrate
apheresis, transforming growth factor beta1, ... 156
blood component, ... 16
buffy coat method, transforming growth factor beta1, ... 156
Platelet concentration, platelet survival, ... 619(E)
Platelet cytoskeleton, ... 997(E), 1004
Platelet function, ... 997(E), 1004
Platelet production, thrombopoietin, ... 449
Platelet recovery, CD34+ cell selection, ... 199, 1063
Platelet substitute, ... 997(E), 1004
Platelet survival
bone marrow transplantation, ... 637
as function of platelet concentration, ... 637
high-dose chemotherapy, ... 637
mathematical modeling, ... 637
platelet concentration, ... 619(E)
platelet transfusion, chronically platelet transfusion-dependent patient, ... 637
thrombocythemia, ... 637
thrombocytopenia, ... 637
Platelet transfusion
bone marrow transplantation, ... 839
consensus conference, ... 707(E)
final statement, ... 796
consensus statement, ... 707(E)
donor platelet counts effects on platelet yields, ... 619(E)
hematopoietic progenitor cell transplantation, ... 839
clinical factors influencing posttransfusion platelet increment, ... 839
HLA antibodies with restricted specificity, ... 839
platelet antibodies, ... 839
posttransfusion (16-hour) corrected count increments, ... 839
serum cyclosporin A, ... 839
serum tacrolimus, ... 839
total bilirubin, ... 839
total body irradiation, ... 839
hypotensive reaction, ... 410(L)
myelosuppressive effect, ... 156
need for consensus, ... 707(E)
platelet function after high dose, ... 619(E)
platelet recovery after high dose, ... 619(E)
platelet survival, chronically platelet transfusion-dependent patient, ... 637
refractory, ... 41
requirements, ... 637
strategies maintaining hemostatic protection, ... 619(E), 997(E), 1004
Platelet transfusion reaction, length of storage, ... 229
Plateletpheresis
Amicus Separator
collection efficiency, ... 848
collection times, ... 848
component yields, ... 848
double apheresis platelet, ... 848
incidence of donor reactions, ... 848
incidence of transfusion recipient reactions, ... 848
residual white cells, ... 848
single apheresis platelet, ... 848
donors' health, ... 454
female donor hemoglobin level, ... 848
platelet activation, interval between plateletpheresis procedures, ... 319(L)/515(L)
reticulated platelet, ... 454
frequent donors, ... 454
new donors, ... 454
Spectra Leukocyte Reduction System
collection effiency, ... 848
collection times, ... 848
component yields, ... 848
double apheresis platelet, ... 848
incidence of donor reactions, ... 848
incidence of transfusion recipient reactions, ... 848
residual white cells, ... 848
single apheresis platelet, ... 848
Spectra Leukoreduction System
collection efficiency, ... 966
component quality, ... 966
determination of degree of conformance with standards, ... 966
evaluation, ... 966
ongoing quality control, ... 966
validation, ... 966
thrombopoiesis, reticulated platelet, ... 454
thrombopoietin, ... 449
female donors, ... 449
male donors, ... 449
normalization of donors' platelet counts, ... 449
Point score system, blood transfusion prediction, ... 932
Poisson's distribution, ... 12, 1119(L)
Polyclonal antihuman globulin reagent, ... 343
Polyethylene glycol, ... 1037
Polymerase chain reaction
allele-specific primers, *Fcγ receptor IIA* polymorphism, ... 174
C733G (Leu245Val) polymorphism, ... 951
controls for sample contamination, ... 1041
cytomegalovirus DNA, ... 271
D-CE hybrid exon 3, ... 951
D variants, genotyping, ... 1015
G1006T (Gly336Cys) polymorphism, ... 951
GB virus C, ... 378
hepatitis C virus, ... 194, 378
plasma pools, ... 908, 915
polyethylene glycol precipitation step, ... 908
preseroconversion window period, ... 908
sensitivity, ... 908
specificity, ... 908
hepatitis G virus, ... 378
human immunodeficiency virus-1 RNA
plasma pools, ... 908
polyethylene glycol precipitation step, ... 908
preseroconversion window period, ... 908
sensitivity, ... 908
specificity, ... 908
partial D genotyping, ... 105, 1015
plasma pool, ... 908
primer, ... 118(E)
design, ... 118(E)
sample contamination, ... 1041
white cell, quantitation using frozen whole blood, ... 262
Y chromosome in female blood sample, ... 1041
Polymorphonuclear leukocyte
count as predictor of CD34+ cell collection efficiency, ... 1046
dexamethasone, ... 713
granulocyte—colony-stimulating factor, ... 713
Polyspecific anti-human globulin, anti-P_1, ... 373
Pooled plasma testing
complication, ... 469
effect of dilution, ... 469
genome amplification technology, ... 469
human immunodeficiency virus-1 RNA genome amplification, effects of dilution, ... 469
Postoperative blood recovery, ... 400
Posttransfusion hepatitis, hepatitis G virus, ... 1097
Posttransfusion purpura, reporting of, ... 999(E), 1071
Potassium, red cell, 24-hour storage at 25°C, ... 424
Prednisone, granulocyte
comparison, ... 722
evaluation, ... 722
mobilization schedules, ... 722
white cell counts, ... 722
Pregnancy
antithrombin III, ... 481
enzyme-only blood group alloantibody, ... 318(L)

GB virus type C, ... 821
hepatitis G virus, ... 821
Preoperative autologous blood donation, ... 400
acute normovolemic hemodilution, compared, ... 473
cost-effectiveness, ... 400
erythropoietin, ... 400
gender variations, ... 392
primary total hip replacement, interhospital variations, ... 530
primary total knee replacement, interhospital variations, ... 530
Preoperative erythropoietin therapy, prostatectomy, ... 924
Preservative solutions and white cell apoptosis, ... 1082
Pretransfusion testing
ABO bedside compatibility test, ... 999(E), 1030
column agglutination technology, ... 1037
immunohematology, ... 343
methods, ... 343
national survey, ... 343
facility size and type, ... 343
reagents, ... 343
Pretransfusion testing instrument
antibody screen, ... 959
crossmatch, ... 959
evaluation, ... 959
forward ABO group, ... 959
reverse ABO group, ... 959
Rh phenotype, ... 959
Rh type, ... 959
variant A antigen, ... 959
variant D antigen, ... 959
weak A antigen, ... 959
weak D antigen, ... 959
Primary light-chain amyloidosis, transplantation, ... 60
tumor cell contamination, ... 60
Primary total hip replacement, preoperative autologous blood donation, interhospital variations, ... 530
Primary total knee replacement, preoperative autologous blood donation, interhospital variations, ... 530
Prion, human albumin, ... 690
Process control in polymerase chain reaction, ... 1041
Procoagulant function of platelets, ... 997(E), 1004
Prostatectomy
acute normovolemic hemodilution, ... 924
autologous blood donation, ... 924
hematocrit, ... 924
perioperative blood conservation, ... 924
preoperative erythropoietin therapy, ... 924
Protein Reviews On the Web (PROW) database, ... 499
Prothrombin fragments 1 and 2, ... 997(E), 1004
Prothrombin time, change after red cell transfusion, ... 1011
P-selectin
cell separator, ... 24
dimethyl sulfoxide, ... 160
flow cytometric analysis, ... 24
gender, ... 24
platelet, ... 24
second messenger effector mixture, ... 160
Pseudomonas putida, ... 1090
Pseudorabies virus, dimethylmethylene blue, ... 729
Psychological distress, of donors who are positive for human T-lymphotropic virus, ... 1056
Purging of tumor cells from CD34+ cells, ... 1063

Q

Quality improvement in reporting errors, ... 999(E), 1030, 1071
Quality plan, ISO 9000 model, ... 79

R

Radioimmunoassay
hepatitis B surface antigen mutant form, ... 56
red cell-bound immunoprotein, ... 782
Receptor-mediated
cell death, ... 1082
hemagglutination assay, human parvovirus B19 DNA, ... 108(L)
Recombinant blood group antigen, ... 658
Recombinant glycophorin A blood group antigen, plasma membrane vesicle, ... 658
anti-M antibody, ... 658
Recombinant immunoblot assay, hepatitis C virus, ... 194
Recording errors in transfusion, ... 999(E), 1030, 1071
Red cell
acute anemia, ... 517(E)
ADP release and hemostasis, ... 1011
ATP, 24-hour storage at 25°C, ... 424
component storage conditions and white cell apoptosis, ... 1082
copper, ... 327
dimethylmethylene blue, ... 729
glucose, 24-hour storage at 25°C, ... 424
hemostatic effect, ... 604, 1011
lactate, 24-hour storage at 25°C, ... 424
lung transplantation, ... 12, 1119(L)
membrane abnormality, red cell-bound immunoprotein, ... 782
paroxysmal nocturnal hemoglobinuria, ... 337
phenotyping with IgM monoclonal antibodies in column agglutination technology, ... 1037
potassium, 24-hour storage at 25°C, ... 424
reticulocyte immunophenotyping, ... 337
sodium, 24-hour storage at 25°C, ... 424
transfusion practice, ... 122, 392
virucidal phototreatment, ... 729
virus inactivation, ... 580
warmed
degree of accelerated metabolism, ... 424
increased hemolysis, ... 424
Red cell acid-elution kit, anti-D, ... 565
Red cell potassium efflux
dimethylmethylene blue, ... 729
phenothiazine derivative, ... 729
Red cell transfusion
anemia, ... 522, 1011
carbon dioxide, ... 602
central blood volume, ... 602
effect on bleeding time, activated thromboplastin time, and prothrombin time, ... 1011
hemoglobin, ... 522
hemostasis, ... 602, 1011
hip fracture
indications for transfusion, ... 522
randomized trial comparing symptomatic *vs.* hemoglobin-level-driven, ... 522
hip surgery, interhospital variations, ... 530
knee surgery, interhospital variations, ... 530
oxygen, ... 602
peripheral blood volume, ... 602
plasma volume, ... 602
prevention of graft-versus-host disease by irradiation or storage for more than 7 days, ... 1117(L)
red cell volume, ... 602
surgical blood order equation
costs, ... 828
crossmatch-to-transfusion ratio, ... 828
incorporating specific patient variables, ... 828
maximal surgical blood order schedule compared, ... 828
total blood volume, ... 602
total hip arthroplasty, prospective randomized trial of surgical blood order equation, ... 828
transmission of graft-versus-host disease after 7-day storage, ... 1117(L)
transfusion history, ... 602
transfusion trigger, ... 602
Red cell-bound immunoprotein
antiglobulin consumption, ... 782
augmented antiglobulin tests, ... 782
autoimmune hemolytic anemia, ... 782
clinical studies, ... 782
direct antiglobulin test, ... 782
enzyme-linked immunosorbent assay, ... 782
flow cytofluorometry, ... 782
hemoglobin, ... 782
immunological disorders, ... 782
measurement, ... 782

quantitation, ... 782
radioimmunoassay, ... 782
red cell membrane abnormality, ... 782
survival studies, ... 1026
Renal dysfunction, antithrombin III, ... 481
Renal insufficiency, ... 327
Replacement-donation program, ... 368
Reporting, mandatory, of transfusion errors, ... 999(E), 1030, 1071
Reticulated platelet, plateletpheresis, ... 454
frequent donors, ... 454
new donors, ... 454
Reticulocyte analyzer and contamination of sample for polymerase chain reaction, ... 1041
Reticulocyte immunophenotyping
immunohematology, ... 337
paroxysmal nocturnal hemoglobinuria, ... 337
red cell, ... 337
Retrovirus Epidemiology Donor Study (REDS), ... 1056
Reverse ABO group
AutoVue System, ... 959
column agglutination technology, ... 959
pretransfusion testing instrument, ... 959
Reverse transcriptase polymerase chain reaction
CD34+ cell selection, ... 60
GB virus type C, ... 821
hepatitis G virus, ... 821
Rh blood group system, genotyping in, ... 1015
Rh immune globulin, gel agglutination technique, ... 177
Rh phenotype, pretransfusion testing instrument, ... 959
Rh testing, monoclonal-polyclonal blended reagent, ... 343
Rh type
AutoVue System, ... 959
pretransfusion testing instrument, ... 959
RhD alloimmunization, ... 97
RHD genotyping
immunohematology, ... 434
Japan, ... 434
multiplex polymerase chain reaction, ... 1015
sequence-specific polymerase chain reaction, ... 434
weak D phenotype, multiple polymerase chain reaction, ... 434
Rosenfield, Richard E., obituary, ... 1115
Rule-based behaviors and errors in transfusion medicine, ... 999(E), 1071

S

Saline-adenine-glucose-mannitol preservative solution and white cell apoptosis, ... 1082
Sample contamination by laboratory equipment before polymerase chain reaction, ... 1041
Saponin, ... 1090
Screening, ... 915
antibody to hepatitis B core antigen, ... 56
fetomaternal hemorrhage, ... 177
hepatitis B surface antigen mutant form, ... 56
hepatitis B virus DNA, ... 56
nucleic acid testing, ... 905
red cell phenotyping with IgM monoclonal antibodies in column agglutination technology, ... 1037
sample pooling, ... 915
viral genome, ... 915
hepatitis C virus RNA detection, ... 915
real-time simulation using pooled samples, ... 915
Scrub typhus, ... 680
storage, ... 680
Second messenger effector mixture
cell number, ... 160
extent of shape change, ... 160
hypotonic shock response, ... 160
percent of discoid cells, ... 160
p-selectin, ... 160
Selection, magnetic, of CD34+ cells, ... 1063
Self-control, of donors who are positive for human T-lymphotropic virus, ... 1056
Septic-toxic syndrome
delayed hemolytic transfusion reaction, ... 459
systemic inflammatory response syndrome mediator, ... 459
Sequence-specific polymerase chain reaction, *RHD* genotyping, ... 434
Serious Hazards of Transfusion (SHOT), ... 999(E), 1071
Serologic test for syphilis, discredited surrogate test for human immunodeficiency virus infection, ... 218(L)
Seroprevalence study, hepatitis A virus, ... 573
Sickle cell disease
antibody detection/development in, ... 1022, 1026
Y chromosome in samples from females, ... 1041
Sickle cell syndrome, ... 1022, 1026
Single-antigen research immunoassay, hepatitis C virus, ... 194
Sixth International Conference on Human Leukocyte Differentiation Antigens, ... 499
Sixth International Workshop on Human Leukocyte Differentiation Antigens, ... 499
Skin
A antigen, ... 975
B antigen, ... 975
Skin transplantation, ABO incompatibility, ... 975
Skill-based behaviors and errors in transfusion medicine, ... 999(E), 1071
Social effects, of donors who are positive for human T-lymphotropic virus, ... 1056
Sodium, red cell, 24-hour storage at 25°C, ... 424
Sodium citrate anticoagulant, ... 242
Solid organ transplantation, hemolysis, ... 225(E)
Soluble p-selectin, ... 24
Solvent/detergent-treated antihemophilic factor VIII concentrate, hepatitis A virus, ... 573
Solvent/detergent-treated plasma, committee report, ... 102
development, ... 102
efficacy, ... 102
impact on blood banking and transfusion practice, ... 102
logistics, ... 102
production, ... 102
safety, ... 102
supply, ... 102
Specialists in Blood Bank Technology, ... 700
job market, ... 700
need for, ... 700
resources for, ... 700
training programs, ... 700
Spectra apheresis machine
comparison of AutoPBSC and Version 4.7 for collection of peripheral blood stem and progenitor cells, ... 1051
pediatric leukapheresis, ... 71
Spectra Leukocyte Reduction System
Amicus Separator, compared, ... 848
plateletpheresis
collection effiency, ... 848
collection times, ... 848
component yields, ... 848
double apheresis platelet, ... 848
incidence of donor reactions, ... 848
incidence of transfusion recipient reactions, ... 848
residual white cells, ... 848
single apheresis platelet, ... 848
Spectra Leukoreduction System, plateletpheresis component
collection efficiency, ... 966
component quality, ... 966
determination of degree of conformance with standards, ... 966
evaluation, ... 966
ongoing quality control, ... 966
validation, ... 966
Spongiform encephalopathy, ... 221(E)
Staphylococcus aureus, ... 1090
Staphylococcus epidermidis, ... 674, 1090
Statistics to describe blood usage, ... 12, 1119(L)
Stem cell
components, false-positive bacterial results in, ... 1090
factors influencing availability, ... 508(L)
STKS blood cell analyzer, ... 1041
Storage
blood component, ... 16

C5a, ... 16
cord blood progenitor cell
temperature, ... 615(L)
time, ... 615(L)
CPDA-1 packed red cell, 24-hour storage at 25°C, ... 424
interleukin 8, ... 16
leukotriene B4, ... 16
Orientia tsutsugamushi, ... 680
glycerolized and frozen at -70°C, ... 680
stored at 4°C, ... 680
platelet, ... 31
CP2D, ... 242
cryopreservation, ... 160
development of transfusion reactions, ... 229
duration, ... 229
long-term, ... 550
plasma volume reduction, ... 242
second messenger effector mixture, ... 160
transforming growth factor beta1, ... 156
platelet concentrate, ... 16
red cell
decrease of immunologic reactivity of lymphocytes during, .. 1117(L)
dimethylmethylene blue, ... 729
scrub typhus, ... 680
tumor necrosis factor alpha, ... 16
white cell apoptosis during, ... 1082
Superoxide dismutase, hepatitis C virus, ... 194
Surgery and transmission of hepatitis G and C viruses, ... 1097
Surgical blood order equation, red cell transfusion
costs, ... 828
crossmatch-to-transfusion ratio, ... 828
incorporates specific patient variables, ... 828
maximal surgical blood order schedule compared, ... 828
Sweden
GB virus C, ... 378
hepatitis C virus, ... 378
hepatitis G virus, ... 378
Syphilis, ... 218(L)
Sysmex R3000 reticulocyte analyzer, ... 1041
System operators, quality assurance, ... 999(E), 1071
Systemic inflammatory response syndrome mediator
anti-D, ... 459
C3a-desArg, ... 459
C-reactive protein, ... 459
direct antiglobulin test, ... 459
elastase, ... 459
exchange transfusion, ... 459
fibrinogen, ... 459
hemolysis, ... 459
interleukin-1, ... 459
interleukin-6, ... 459
interleukin-8, ... 459
interleukin-10, ... 459
neopterin, ... 459
septic-toxic syndrome, ... 459
tumor necrosis factor, ... 459
Systemic oxygenation
hemodilution, ... 135
hyperoxic ventilation, ... 135

T

Tachycardia, hematocrit, ... 924
Taiwan
anti-E2, ... 290
hepatitis G virus, ... 290
human T-cell lymphotropic virus prevalence in donors, .. 1118(L)
Technical errors in transfusion medicine, ... 999(E), 1071
Terminal complement complex
apheresis, ... 16
platelet concentrate, ... 16
white cell reduction, ... 16
Thalassemia
hepatitis G virus
genetic heterogeneity, ... 301
immunity to hepatitis G/GB-C virus, ... 301
multiply transfused patients, ... 301
NS3 gene, ... 301
reverse transcriptase-polymerase chain reaction assay, ... 301
sequence analysis, ... 301
viremia, ... 301
red cell transfusion and anemia in, ... 1011
transfusion complication, ... 301
Y chromosome in samples from females, ... 1041
Thiazole orange, ... 337
Third International Workshop on Monoclonal Antibodies against Red Cell and Related Antigens, ... 1015
Three-cell antibody-screening test, ... 343
Thrombin, ... 997(E), 1004
Thrombocythemia, platelet survival, ... 637
Thrombocytopenia, platelet survival, ... 637
Thrombogenicity of platelet substitute, ... 997(E), 1004
Thrombopoietin
apheresis, ... 449
blood donor, ... 449
enzyme-linked immunosorbent assay, ... 449
megakaryocytopoiesis, ... 449
platelet production, ... 449
plateletpheresis, ... 449
female donors, ... 449
male donors, ... 449
normalization of donors' platelet counts, ... 449
reticulated platelet, ... 454
Thrombopoietin therapy, ... 9
Thrombotic thrombocytopenia, antimicrobial therapy, ... 419
Thrombotic thrombocytopenic purpura, ... 225(E)
endothelial injury, ... 419
etiology, ... 419
plasma exchange, ... 834
occult infection, ... 419
platelet aggregation, ... 419
refractory, ... 419
occult bacterial infection, ... 419
Tissue factor pathway, ... 997(E), 1004
Tissue oxygenation
hemodilution, ... 145
intravenous perflubron emulsion, ... 145
Tissue transplantation, histo-blood group ABO system, ... 975
Total blood volume, red cell transfusion, ... 602
Total hip arthroplasty, red cell transfusion, prospective randomized trial of surgical blood order equation, ... 828
Tracking of errors in transfusion medicine, ... 999(E), 1071
Training
In MERS-TM system, ... 999(E), 1071
insufficient and errors in bedside compatibility testing, ... 999(E), 1030
Transforming growth factor β_1
hematologic malignancy, after transfusion of platelet concentrates, ... 156
inhibitor of bone marrow proliferation, ... 156
Transfusion Alliance, ... 887
accomplishments, ... 887
future direction, ... 887
organization, ... 887
rationale, ... 887
Transfusion complication, ... 307
ABO-incompatible plasma, ... 51
ABO incompatibility, ... 999(E), 1030, 1071
anti-D, ... 459
anti-P_1, ... 373
autologous blood transfusion, ... 296
bacterial contamination, ... 674, 1090
Creutzfeldt-Jakob disease, ... 810, 817
delayed hemolytic transfusion reaction, ... 459, 1022, 1026
febrile reaction, ... 41
GB virus type C, ... 378, 821
graft-versus-host disease, ... 1117(L)
hepatitis A, ... 573
hepatitis B virus, ... 905
hepatitis B virus mutant form, ... 56
hepatitis C virus, ... 194, 378, 905, 908, 915, 1097

hepatitis E, ... 589
hepatitis G virus, ... 301, 307, 378, 821, 1097
human herpesvirus 8, ... 771
human immunodeficiency virus, ... 776, 905
human immunodeficiency virus-1, ... 580
human immunodeficiency virus-1nocturnal, ... 908
human immunodeficiency virus-2, ... 189
human T-lymphotropic virus types I and II, ... 1056, 1118(L)
platelet component bacteria, ... 674
pooled plasma testing, ... 469
reporting of, ... 999(E), 1030, 1071
scrub typhus, ... 680
thalassemia, ... 301
transmissible spongiform encephalopathy, ... 810
Transfusion medicine
European testing requirements, ... 506(L)
funding, ... 899(E)
history, ... 899(E)
status of, ... 899(E)
Transfusion practice
copper, ... 327
gender, ... 392
allogeneic transfusion in cardiac surgery, ... 392
allogeneic transfusion in orthopedic surgery, ... 392
cryoprecipitate, ... 392
fresh-frozen plasma, ... 392
intraoperative hypothermia, ... 392
platelets, ... 392
preoperative autologous blood donation, ... 392
hematocrit, ... 924
hip arthroplasty, ... 738
autologous blood conservation strategies, ... 738
coronary artery bypass graft surgery
all blood components, ... 122
interhospital differences, ... 122
red cell, ... 122
variation by surgeon, ... 122
hematopoietic progenitor cell transplantation, ... 839
hemodilution, ... 135, 145
hyperoxic ventilation, ... 135
intravenous perflubron emulsion, ... 145
lung transplantation, ... 12, 1119(L)
number of red cell units, ... 738
perflubron, ... 145
perioperative red cell units, ... 738
plasma, ... 834
platelet, ... 839
postoperative red cell units, ... 738
red cell, ... 122, 828
timing of transfusion, ... 738
Japan, prevention of graft-versus-host disease, ... 1117(L)
knee arthroplasty, ... 738
autologous blood conservation strategies, ... 738
number of red cell units, ... 738
perioperative red cell units, ... 738
postoperative red cell units, ... 738
timing of transfusion, ... 738
plasma exchange, occult infection, ... 419
platelet survival, ... 637
red cell, ... 392, 522, 530, 1117(L)
reporting errors in, ... 999(E), 1030, 1071
surgery and transmission of hepatitis G virus and hepatitis C virus, ... 1097
United States,1994, ... 625
Transfusion reaction, autologous blood transfusion
allergic reaction, ... 296
febrile nonhemolytic reaction, ... 296
incidence, ... 296
Transfusion risk, Paling Perspective Scale expression of, ... 184
Transfusion safety
bedside ABO-compatibility testing, ... 1030
blood donor, ... 323(E)
blood donor characteristics, ... 323(E)
Creutzfeldt-Jakob disease, ... 221(E)
donor pool size and risk, ... 312
graft-versus-host disease prevention by irradiation or transfusion of red cells stored for more than 7 days, ... 1117(L)
realigning efforts with risks, ... 410(L)
zero-risk blood supply, ... 221(E)
Transfusion-associated sepsis
cytokine, ... 703(L)
endotoxin, ... 703(L)
Transfusion-related acute lung injury, reporting of, ... 999(E), 1071
Transmissible spongiform encephalopathy
albumin, ... 810
blood component
Cohn plasma fraction, ... 810
distribution of infectivity, ... 810
experimental models, ... 810
scrapie, ... 810
cryoprecipitate, ... 810
factor VIII, ... 810
fraction I+II+III, ... 810
fraction IV, ... 810
fraction V, ... 810
plasma derivative, distribution of infectivity, ... 810
TRANSNAB Study, ... 1097
Transplantation. *See also* Specific type
cancer, hematopoietic recovery, ... 199
CD34+ cell selection, ... 60, 1046
hematopoietic stem cell component, ... 1(E)
hemolysis, ... 224(E)
ABO-incompatible allogeneic marrow transplant, ... 225(E)
autoimmune hemolytic anemia, ... 225(E)
bystander immune hemolysis, ... 225(E)
Clostridium perfringens, ... 225(E)
drug administration, ... 225(E)
hemolytic-uremic syndrome, ... 225(E)
major ABO blood group incompatibility, ... 225(E)
minor ABO-incompatible allotransplantation, ... 224(E)
passenger lymphocyte syndrome, ... 224(E)
passive transfer of antibody, ... 225(E)
thrombotic thrombocytopenic purpura, ... 225(E)
number of peripheral blood CD34+ cells, ... 385, 1046
peripheral blood progenitor cell collection, pediatric, ... 70
primary light-chain amyloidosis, ... 60
tumor cell contamination, ... 60
Y chromosome microchimerism, ... 1041
Trypanosoma cruzi, blood donor, screening in nonendemic area of Brazil, ... 611(L)
Trypsin-only anti-D, ... 318(L)
Tumor cell purging from CD34+ cells, ... 1063
Tumor necrosis factor
delayed hemolytic transfusion reaction, ... 459
systemic inflammatory response syndrome mediator, ... 459
Tumor necrosis factor alpha
filtration, ... 16
storage, ... 16
white cell reduction, ... 236
Turkey
hemophilia, ... 798(L)
hepatitis C virus, ... 798(L)
Two-angle light scatter, white cell-reduced platelet concentrate, 650
Two-color flow cytometry, ... 337

U

United States
1994 collection and transfusion, ... 625
1992 compared, ... 625
clotting factor concentrate hepatitis A virus, ... 573
human T-lymphotropic virus type I *tax* sequence, ... 800(L)
Unrelated-donor bone marrow transplantation, consensus conference, ... 100
decision-making, ... 100
donor, ... 100
efficacy, ... 100
indications, ... 100

toxicity, ... 100

V

V blood group polymorphism
in Africans, ... 951
molecular analysis, ... 951
serologic analysis, ... 951
Val245, ... 951
Variant A antigen
AutoVue System, ... 959
column agglutination technology, ... 959
pretransfusion testing instrument, ... 959
Variant D antigen
AutoVue System, ... 959
column agglutination technology, ... 959
pretransfusion testing instrument, ... 959
Venooclusive disease, bone marrow transplant, antithrombin III, ... 481
Version 4.7 system, collection of peripheral blood stem and progenitor cells, ... 1051
Vesicular stomatitis virus, dimethylmethylene blue, ... 729
Vinca alkaloid, ... 225(E)
Viral disease, risk of transmission, ... 102
Viral genome, screening, ... 915
hepatitis C virus RNA detection, ... 915
real-time simulation using pooled samples, ... 915
Virucidal phototreatment, red cell, ... 729
Virus-inactivation procedure, ... 102
Virus-neutralizing antibody, human albumin, ... 690
Vitality, of donors who are positive for human T-lymphotropic virus, ... 1056
VS blood group polymorphism
in Africans, ... 951
molecular analysis, ... 951
serologic analysis, ... 951

W

Weak A antigen
AutoVue System, ... 959
column agglutination technology, ... 959
pretransfusion testing instrument, ... 959
Weak D antigen
AutoVue System, ... 959
column agglutination technology, ... 959
pretransfusion testing instrument, ... 959
Weak D phenotype
genetic diversity, ... 434
RHD genotyping, multiple polymerase chain reaction, ... 434
Wellness, of donors who are positive for human T-lymphotropic virus, ... 1056
Western blot
false-reactive, ... 776
human immunodeficiency virus-2, ... 189
White cell
apoptosis in stored blood components, ... 1082
carbon dioxide production by and false-positive result in bacterial testing, ... 1090
count as predictor of CD34+ cell collection efficiency, ... 1046
cytokine, ... 236
fresh-frozen plasma
fast filtration, ... 645
filter capacity, ... 645
flow cytometry, ... 645
hard-spin method, ... 645
second-spin method, ... 645
slow filtration, ... 645
soft-spin method, ... 645
microchimerism after transfusion or transplantation, ... 1041
nucleic acid analysis, frozen whole-blood samples, ... 262
polymerase chain reaction, quantitation using frozen whole blood, ... 262
White cell reduction
C3 activation product, ... 16
chemotaxin, ... 16
Creutzfeldt-Jakob disease, ... 221(E)
filtration, ... 317(L)
human T-cell lymphotropic virus type I
Tax proviral sequence, ... 317(L)
Tax-encoded protein, ... 317(L)
interleukin-1β, ... 236
interleukin-2, ... 236
interleukin-6, ... 236
interleukin-8, ... 236
platelet concentrate, hypotensive reactions, ... 410(L)
terminal complement complex, ... 16
tumor necrosis factor α, ... 236
White cell reduction system, ... 848
White cell subset
apheresis, ... 650
detection, ... 650
platelet concentrate, ... 650
presence in platelet components, ... 650
quantification, ... 650
White cell-reduced platelet concentrate
apheresis system
clinical trial, ... 966
collection efficiency, ... 966
component quality, ... 966
determination of degree of conformance with standards, ... 966
ongoing quality control, ... 966
validation, ... 966
fluoflow cytometry, ... 650
human immunodeficiency virus-1
after storage, ... 580
compartmentalization of human immunodeficiency virus-1, ... 580
immediately after component preparation, ... 580
two-angle light scatter, ... 650
White cell-reduced red cell, ... 729
blood component, ... 429
human immunodeficiency virus-1
after storage, ... 580
compartmentalization of human immunodeficiency virus-1, ... 580
immediately after component preparation, ... 580
quality control, ... 429
simplified counting, ... 429
white cell preservation, ... 429
White cell-reduction filter
fresh-frozen plasma
fast filtration, ... 645
filter capacity, ... 645
flow cytometry, ... 645
second-spin methods, ... 645
slow filtration, ... 645
soft-spin methods, ... 645
hypotensive reaction, ... 410(L)
platelet concentrate, ... 650
granulocyte, ... 650
monocyte, ... 650
White-cell counting technique, ... 429
Whole blood, direct freezing, ... 262
Whole-virus lysate enzyme immunoassay, human immunodeficiency virus-2, ... 189
Wu blood group polymorphism
Gly_{565}→Ala substitution in human erythroid band 3, ... 745
serologic investigations, ... 745

X

Xenotransplant, ... 9

Y

Y-chromosome-specific polymerase chain reaction, ... 262, 1041
Yersinia enterocolitica
antibody screening, ... 511(L)
blood donor, ... 511(L)

Z

Zimbabwe, human immunodeficiency virus, ... 279